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ABSTRACT

New methodologies for in vitro analysis of binding
and functional activity of sigma receptor ligands
JAMES A FISHBACK
Sigma receptors represent a promising drug development target for a number of therapeutic indications
including cancer, depression, psychostimulant abuse and stroke. To date, two subtypes of sigma receptors
have been identified; σ1 and σ2. Their respective roles in normal physiology and in disease processes are
a subject of ongoing studies. Consequently, the discovery and development of subtype specific agonist
and antagonist ligands remains a key research goal. To date, no in vitro functional assay suitable for
routine screening of putative sigma ligands has been reported. As a result, radioligand binding assays are
used as a primary screen. Therefore, to support the critical role of receptor binding assays, a new σ1
selective radioligand, [3H]-SN56, was characterized, and efforts were undertaken to develop medium
throughput methods for binding affinity determinations for both sigma receptor subtypes. To fill the
unmet need for an in vitro functional assay for σ1 ligands, preliminary studies were performed to develop
an immunological assay based on the ligand sensitive interaction of σ1 and binding immunoglobulin
protein (BiP). The results of the studies with [3H]SN56 show that it possesses high affinity and selectivity
for σ1 receptors and offers considerable advantages over the currently used radioligand, [ 3H](+)pentazocine. Competition binding studies with established sigma ligands assayed in rat brain
homogenates labeled with [3H]SN56 or [3H](+)-pentazocine yielded comparable Ki values, indicating that
the two radioligands bind the same site. Saturation studies revealed similar Bmax values for [3H]SN56 and
[3H](+)-pentazocine, further supporting the notion that both ligands bind specifically to the site identified
as the σ1 receptor. Conventional radioligand binding studies for sigma receptors utilize a “cell harvester.”
Newer medium and high throughput technologies exist that have been applied to the analysis of numerous
classical receptors. 96-well filtration and scintillation proximity assay (SPA) were evaluated for the
analysis of sigma receptor ligand binding. Adaptation of the conventional binding assay to the higher
throughput methods required the use of rat liver membranes because sigma receptor densities were too
low in rat brain membranes to support reliable filtration in the 96-well format or use with SPA. Analysis
of a series of reference compounds by 96-well filtration yielded binding affinities that correlated with
values measured using the conventional method, for both sigma receptor subtypes. Following validation
with the reference compounds, the 96-well filtration procedure was successfully used to determine K i
values for sigma receptors for a novel series of 2(3)-benzothiazolones. Studies with SPA demonstrated
that this technique also yields results that are equivalent to the conventional method, but the cost of beads
is prohibitively high with currently available radioligands used in conjunction with tissue derived
membranes; this cost could potentially be significantly reduced if higher specific activity radioligands
were available or if membranes from cells overexpressing sigma receptors were utilized. Preliminary
studies were performed to assess the feasibility of developing a high throughput in vitro functional assay
for the σ1 receptor using Alphascreen as a read-out of agonist induced disruption of the σ1/BiP complex.
These efforts, which included a basic assessment of the Alphascreen platform, and attempts to determine
if endogenous or recombinant proteins could serve as suitable substrates, were largely unsuccessful.
However, these experiments did yield information that should prove useful for future development of an
in vitro functional assay based on this protein-protein interaction.
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CHAPTER 1
Background and objectives

1

1.1. Sigma receptors
The sigma receptor was first described as a subtype of opioid receptors based on behavioral
observations in dogs following administration of the benzomorphan, N-allylnormetazocine
(SKF10,047) [1]. Subsequent in vitro observations indicated that this binding site represented a
new class of non-opioid receptor [2, 3]. Sigma receptors are widely distributed in the body with
significant concentrations in most major organs, including the brain, heart, liver, kidney and
spleen [4-8]. In the brain, they are found predominantly in structures associated with limbic and
endocrine function, including the hippocampus, frontal cortex, hypothalamus, and olfactory bulb
[9, 10].
Two subtypes of sigma receptors, σ1 and σ2, have been identified based on differences in
pharmacological profile, tissue distribution, and molecular characterization [6, 11-15]. Their
respective roles in normal physiology and in disease processes are a subject of ongoing
pharmacological studies. The successful cloning, recent advances in the understanding of the
functional role of σ1 at the molecular level, and the availability of σ1 subtype specific ligands
provide some of the necessary tools for rational therapeutic targeting of this ubiquitous protein.
However, existing knowledge of σ2 is more limited, rendering specific targeting of this subtype
problematic.
The σ1 receptor is a highly conserved 223 amino acid protein that has been cloned from several
species, including rodents and humans [16-20]. Functionally, σ1 receptors appear to operate
primarily via protein-protein interactions and have been shown to modulate the activity of
various ion channels and signaling molecules [21]. σ1 receptors are expressed on the
endoplasmic reticulum (ER) and can translocate between different cellular compartments in
response to ligand binding [22-24]. Accordingly, the discrete activities that are ascribed to the σ1
receptor depend on its cellular location. σ1 mediated modulation of ion channels on the
plasmalemma [25-30] and control of intracellular calcium via interactions with inositol
trisphosphate (IP3) receptors on the ER are well documented [31-35]. The endogenous ligand(s)
for σ1 have yet to be conclusively identified; however, a number of candidates have been
proposed, including some neuroactive steroids, sphingolipids, and most recently N,Ndimethyltryptamine [36-38].
2

Considerably less is known about the σ2 receptor because selective ligands for this subtype have
not been available, and attempts to isolate the protein have been unsuccessful [39, 40]. Efforts
over the last decade to develop σ2 specific ligands have met with some success, enabling more
concise determinations of σ2 specific effects [41-43]. Sigma receptors, particularly σ2 are
overexpressed in cancer cells and σ2 agonists can inhibit their proliferation and induce apoptotic
cell death by altering cytosolic Ca2+, ceramide and sphingolipid levels [42, 44, 45]. Because σ2
receptors are overexpressed in cancer cells they can function as endogenous markers for
proliferating tumors. Consequently, considerable effort has been expended in developing σ2
specific radioprobes for SPECT (single-photon emission computed tomography) and PET
(positron emission tomography) imaging [46-49].

1.2. Utility of radioligands and radioligand binding methods in sigma receptor research
Application of in vitro binding studies with sigma receptor specific radioligands has resulted in:
1) identification of sigma receptors as unique non-opioid receptors [2, 3], 2) identification of two
sigma receptor subtypes, σ1 and σ2 [12-14], 3) delineation of their anatomical distributions [4,
50-52], and 4) determination of binding affinities of novel compounds. More recent reports show
significant interest in the development of sigma subtype specific radioligands for PET and
SPECT imaging [46-49, 53-56]. These imaging agents may prove useful in: 1) mapping sigma
receptors in the human brain, 2) the diagnosis of cancer [48, 53, 56], Alzheimer’s and
Parkinson’s disease [55], and 3) in the evaluation of antidepressant therapeutics [54].
1.3. σ1 selective radioligands
DeCosta et al. [57] first described [3H](+)-pentazocine, a highly selective radioprobe for σ1
receptors. Subsequent studies demonstrated that [3H](+)-pentazocine labeled a single class of
sites in guinea-pig brain that correlated with the profile observed following labeling with the
prototypic sigma probe [3H](+)-3-PPP ((+)-3-(3-hydroxyphenyl)-N-(1-propyl)-piperidine) [58].
[3H](+)-Pentazocine exhibits low levels of non-specific binding and high affinity for σ1 receptors
(Kd = 4.8 ± 0.4 nM), with an over 700-fold preference for the σ1 over the σ2 subtype [58]. Since
the introduction of [3H](+)-pentazocine, no alternative has been introduced that demonstrates
superior σ1 selectivity and specificity. A number of new radioligands have been proposed, but
each of them has shortcomings: [3H]BHDP (N-benzyl-N'-(2-hydroxy-3,4-dimethoxybenzyl)-
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piperazine) demonstrates moderate affinity for 5-HT2B receptors (IC50 = 190 nM), while
[3H]SA4503

(1-(3,4-dimethoxyphenethyl)-4-(3-phenylprophyl)

piperazine)

lacks

subtype

selectivity, with only 14-fold higher affinity for σ1 versus σ2 reported for unlabeled SA4503,
and

[3H]-MS377

((R)-(+)-1-(4-chlorophenyl)-3-[4-(2-methoxyethyl)piperazin-1-yl]methyl-2-

pyrrolidinone L-tartrate) displays slow association kinetics, which renders its routine use
impractical [59-62]. In recent years, the availability and quality of commercially available
[3H](+)-pentazocine has become unreliable, creating some urgency for the development of an
acceptable alternative radioligand for σ1 receptors. [3H](+)-Pentazocine also demonstrates
instability that manifests in increased non-specific binding as the material ages.
1.4. SN56, [3H]SN56, and novel analogues of SN56
SN56 (3-(2-(azepan-1-yl)ethyl)-6-propylbenzo[d]thiazol-2(3H)-one) was recently identified as a
highly selective and subtype-specific ligand with subnanomolar affinity for 1 receptors [63].
Because of its high affinity and unique selectivity profile, SN56 was chosen for evaluation as a
tritiated radioligand for use in competition binding assays. Additionally, a series of analogues of
SN56 were synthesized by collaborators (Rohit Bhat in the lab of Dr. Christopher McCurdy,
University of Mississippi, University, MS) to further delineate relationships between structure
and binding affinity among this class of compounds. Three general themes were explored in this
benzothiazolone series which include variations in: 1) the size of the attached heterocycle, 2) the
heterocycle linker chain length, and 3) the composition of the alkyl or acyl chain at position 6 of
the benzothiazolone system. This series of compounds were analyzed as part of this dissertation
using the medium throughput 96-well filtration binding method described in this document.

1.5. Medium and high throughput binding methods
Instrumentation and materials have been developed for higher throughput receptor binding
analyses employing filtration and scintillation proximity assays (SPA) in 96-well formats. These
assays are in widespread use in binding experiments with membrane bound receptors (e.g.
serotonin, opioid, somatostatin, acetylcholine) derived from tissue, and cultured cell-derived
membranes [64-68]. In addition to increasing throughput, these assay technologies have the
potential to improve assay accuracy and precision, and reduce costs relative to conventional
filtration based assays [68-73]. Filtration assays in the 96-well format are operationally
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equivalent to conventional filtration assays except that reduced sample sizes are utilized and 96well specific cell harvesters and scintillation counters that can accommodate the 96-well format
are employed for sample processing. Scintillation proximity assays (SPA) utilize scintillant
containing microscopic beads which produce photons when radiolabeled molecules are in close
proximity to the bead surface [70, 74]. Cell membranes associate with the beads via interactions
between wheat germ agglutinin bound to the bead surface and cell membrane glycosylation sites
[70, 74]. Binding of radioligands to receptors present in the membranes and associated with the
treated bead surface give rise to a signal commensurate with the amount of bound radioligand
[70, 74]. Published reports of the use of 96-well filtration in the analysis of sigma receptor
binding are limited to two research groups, the Mach group from Washington University [75-78]
and the Wünsch group from the University of Münster [79, 80]; therefore, it is apparent that the
technique is not in widespread use in the sigma receptor field. To date no reports of the use of
SPA in the analysis of sigma receptor ligands have been published in the literature.
1.6. Binding of sigma ligands in mammalian liver versus brain derived isolates
Development of higher throughput methods for analysis of binding of sigma receptors requires
higher densities of sigma receptors than are expressed in rat or guinea-pig brain P2 membranes.
Several researchers have reported high densities of both sigma receptor subtypes in guinea-pig
and rat liver tissues [6, 16, 52]. Representative Bmax values determined for σ1 and σ2 in rat brain
P2 are ~300-500 fmol/mg and ~1000 fmol/mg, respectively [81, 82], while representative Bmax
values determined for σ1 and σ2 in rat liver P2 are approximately 3 pmol/mg and 9 pmol/mg,
respectively [6]. The six to ten-fold higher density of σ1 receptors in rat liver, relative to rat
brain, is expected to facilitate the use of high throughput radioligand binding methods with the
constraints imposed by conditions required to prevent radioligand depletion and sample size
limitations imposed by the higher throughput formats. Reports on rigorous direct comparisons of
binding of σ1 ligands in isolates from rat brain versus rat liver labeled with [3H](+)-pentazocine
support the pharmacological equivalency of receptors derived from the two tissues [16, 59, 83].
Most contemporary binding studies for σ2 already employ rat liver P2 membranes so no change
of receptor source is required for adapting σ2 assays to the higher throughput methods [43, 80,
84-88].
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1.7. Ca2+ and ligand sensitive interaction of σ1 with binding immunoglobulin
Binding immunoglobulin protein (BiP/GRP78) is a Ca2+ binding ER chaperone that functions as
an ER Ca2+ buffer, modulates the unfolded protein response (UPR), and aids in protein folding
[89, 90]. In 2007 Hayashi and Su [91] reported that the interaction of σ1 with BiP regulates Ca2+
signaling between the ER and mitochondria via IP3 receptors localized at focal points called the
mitochondrial associated membrane (MAM). Evidence for a σ1/BiP complex was obtained from
wild-type CHO (Chinese hamster ovary) cells by co-immunoprecipitation of a σ1/BiP complex
using anti-bodies for either protein [91]. This complex was found with or without chemical
crosslinking prior to cell lysis, suggesting that the interaction occurs endogenously and is not an
isolation artifact [91]. The sensitivity of the σ1/BiP protein complex to sigma agonists and Ca2+
was unequivocally demonstrated in isolates from CHO cells expressing σ1-EYFP (enhanced
yellow fluorescent protein) [91]. Co-immunoprecipitation studies with crude cell lysates from
CHO cells expressing σ1-EYFP exposed in situ to σ1 agonists, showed a dose-dependent
decrease in co-precipitated BiP protein following immunoprecipitation with an anti-EYFP linked
sepharose affinity matrix [91]. Application of 1 antagonists in this system prevented the action
of agonists but had little effect or slightly promoted formation of the complex when they were
administered alone [91].
1.8. Alphascreen technology
Alphascreen is a well developed assay technology marketed by Perkin Elmer (Waltham, MA)
with proven applications in the detection of low to high affinity protein interactions in samples of
purified recombinant, membrane bound, and solubilized proteins from cells and tissues [92, 93].
The basis for the Alphascreen is the generation of a luminescent signal when the “donor” and
“acceptor” beads are brought into close proximity by association of proteins captured on the
respective beads [92, 93]. This general property can be exploited in both signal increasing and
signal decreasing assays, which are well represented by kits available from Perkin Elmer for
assaying interactions as diverse as receptor/ligand interactions, kinase and protease assays and
ELISA-type immunoassays [92, 93]. A recently described assay of inhibitors of the interaction of
heat shock protein 90 (Hsp90) and its co-chaperone, heat shock organizing protein (HOP),
demonstrates the successful application of this technology in the analysis of small molecule
inhibitors of a protein-protein interaction [94, 95]. Some advantages of the Alphascreen
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technology include, 1) numerous available bead chemistries, permitting the detection of diverse
protein interactions with flexible assay design options, 2) high sensitivity with low signal to
background ratio, and 3) adaptability to miniaturization and high throughput screening (HTS).

1.9. Applications for high throughput methods in sigma receptor research
In addition to routine analysis of putative novel sigma ligands, high throughput binding and
functional assays for σ1 receptors may be suitable for screening compound libraries such as the
Prestwick Chemical Library (Washington, DC), a library composed of 1200 FDA-approved
(U.S. Food and Drug Administration) small molecule drugs with high chemical and
pharmacological diversity. The results could identify new compounds, or structural or
pharmacological classes of compounds whose therapeutic activity may be due, in part, to
interaction with σ1 receptors. Antidepressants are an example of a druggable pharmacological
class with varying chemical structures that demonstrate affinity for the sigma receptor [96]. The
availability of a medium or high throughput functional assay would also facilitate tests for
correlation between binding affinity and functional activity for these and other classes of current
and future therapeutics.

1.10 Summary
Radioligand binding approaches remain an essential component for the discovery and
development of novel sigma receptor ligands that have potential use as therapeutics and as
imaging probes. New novel radiolabeled probes and advances in high throughput radioligand
binding technologies provide an opportunity to significantly improve performance standards for
this critical phase of drug discovery. The successful development of an in vitro functional assay
for the σ1 receptor would bring a powerful analytical tool that is not currently available to sigma
receptor research. New capabilities enjoyed as a result of these efforts are anticipated to aid in
the discovery and design of future drug development candidates as well as provide further insight
into the structure and function of the σ1 receptor subtype.

7

1.11 Research objectives
The objective of these studies was to develop new in vitro tools to examine the binding and
functional activity of sigma ligands by addressing the following specific aims:

Aim I
Demonstrate the suitability of [3H]SN56 for use in conventional radioligand binding assays.

Aim II
Develop medium throughput assays for the determination of binding affinities of novel σ ligands.

Aim III
Perform preliminary studies to support the development of a high throughput in vitro functional
assay for σ1 ligands based on the agonist sensitive interaction between σ1 and BiP.
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CHAPTER 2
Synthesis and characterization of [3H]SN56, a novel
radioligand for the σ1 receptor

The material in this chapter was published in part in the European Journal of Pharmacology as
follows:
Synthesis and characterization of [3H]-SN56, a novel radioligand for the σ1 receptor. Fishback
JA, Mesangeau C, Poupaert JH, McCurdy CR, Matsumoto RR. Eur J Pharmacol 2011 Feb
25;653(1-3):1-7
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2.1 Abstract
The study of the binding characteristics of σ ligands in vivo and in vitro requires radiolabeled
probes with high affinity and selectivity. The radioligand presently used for in vitro studies of the
σ1 receptor, [3H](+)-pentazocine, has significant limitations: it is difficult to synthesize, has
limited chemical stability, and can be problematic to obtain. Evaluation of a series of novel
2(3H)-benzothiazolone compounds revealed SN56 to have subnanomolar and preferential
affinity for the σ1 subtype, relative to σ2 and non-sigma, binding sites. The goal of this study
was to characterize the binding of [3H]SN56 to σ1 receptors isolated from rat brain. Standard in
vitro binding techniques were utilized to 1) determine the specificity and affinity of binding to
σ1 receptors, 2) confirm that [3H]SN56 labels sites previously identified as σ1 by comparing
binding to sites labeled by [3H](+)-pentazocine, and 3) characterize the kinetics of binding. The
results indicate that [3H]SN56 exhibits 1) specific, saturable, and reversible binding to the σ1
receptor, with Bmax = 340 ± 10 fmol/mg and Kd = 0.069 ± 0.007 nM, 2) competitive
displacement by classical sigma compounds, yielding σ1 Ki values consistent with those reported
in the literature, and 3) binding kinetics compatible with a 90 min incubation, and filtration for
separation of free and bound radioligand. The results of these studies suggest that [ 3H]SN56 may
serve as a viable alternative to [3H](+)-pentazocine in radioligand binding assays.
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2.2 Introduction

The sigma receptor was first identified as an opioid receptor subtype based on behavioral studies
of morphine-like drugs in dogs [1]. Subsequent in vitro binding data revealed that this site
represents a new class of non-opioid receptor [2]. To date, two subtypes of sigma receptors (σ1
and σ2) have been identified based on differences in ligand selectivity, tissue distribution, and
molecular characterization [3]. The σ1 receptor has been cloned from multiple species [4-9] and
a significant number of ligands with high affinity and selectivity for it are available. The σ2
receptor is less well characterized; it has not been cloned, and few specific ligands have been
described.
The σ1 receptor is involved in numerous physiological processes and disease states, and in vivo
and in vitro studies indicate that modulation of σ1 receptors using sigma specific ligands can
affect these systems [10-13]. Consequently, the σ1 receptor is recognized as a potential
medication development target and efforts to identify novel selective compounds are ongoing.
While the σ2 receptor may also represent a feasible drug development target, further research in
this area will require the discovery of additional selective ligands for this subtype. The focus of
the current work is therefore limited to the characterization of σ1 binding.
DeCosta et al. [14] first described [3H](+)-pentazocine, a highly selective radioprobe for σ1
receptors. Subsequent studies demonstrated that [3H](+)-pentazocine labeled a single class of
sites in guinea-pig brain that correlated with the profile observed following labeling with the
prototypic σ1 probe [3H](+)-3-PPP ((+)-3-(3-Hydroxyphenyl)-N-(1-propyl)-piperidine) [15].
[3H](+)-Pentazocine exhibited low levels of non-specific binding and high affinity for σ1
receptors (Kd = 4.8 ± 0.4 nM), with >700-fold preference for the σ1 over the σ2 subtype [15].
[3H](+)-Pentazocine does, however, exhibit shortcomings, including poor chemical stability,
which limits its usefulness in routine studies.
Efforts to design new σ1 specific ligands have produced a limited number of radioprobes useful
for exploring the pharmacology of the σ1 receptor. Unfortunately, like [3H](+)-pentazocine, each
of the proposed new radioprobes exhibits limitations, such as slow association kinetics, marginal
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sigma subtype selectivity, or nanomolar affinity for other receptors. Therefore, we sought to
characterize the performance of SN56 (3-(2-(azepan-1-yl)ethyl)-6-propylbenzo[d]thiazol-2(3H)one), a novel σ1 selective, 2(3H)-benzothiazolone compound, as a tritiated radioligand, for use in
σ1 competition binding experiments. SN56 exhibited sub-nanomolar affinity (Ki σ1 = 0.56 nM)
and >1,000 fold selectivity for the σ1 subtype relative to the σ2 subtype in guinea-pig brain
membranes, and at least 350-fold greater affinity for the σ1 receptor versus a battery of receptors
and transporters [16]. These binding characteristics coupled with a simple and economical
synthetic scheme suggested [3H]SN56 may provide a viable alternative to [3H](+)-pentazocine in
competition binding studies of the σ1 receptor.

2.3 Materials and Methods

2.3.1 Reagents and chemicals
Reagents and starting materials for the synthesis of SN56 were obtained from commercial
suppliers and were used without purification. Pre-coated silica gel GF Uniplates from Analtech
(Newark, DE) were used for thin-layer chromatography (TLC). Column chromatography was
performed on silica gel 60 (Sorbent Technologies, Atlanta, GA). 1H and 13C NMR spectra were
obtained on a Bruker APX400 (Billerica, MA) at 400 and 100 MHz, respectively. High
resolution mass spectra (HRMS) were recorded on a Waters Micromass Q-Tof Micro mass
spectrometer with a lock spray source (Milford, MA). Mass spectra (MS) were recorded on a
WATERS ACQUITY Ultra Performance LC (Milford, MA) with ZQ detector in ESI mode.
Elemental analysis (C, H, N) was performed on a Perkin-Elmer CHN/SO Series II Analyzer
(Waltham, MA). Chemical names were generated using ChemDraw Ultra (CambridgeSoft,
version 10.0, Cambridge, MA). [3H](+)-Pentazocine (29 Ci/mmol) was purchased from Perkin
Elmer (Boston, MS). (+)-SKF10,047 ((−)-N-allylnormetazocine hydrochloride), (+)-pentazocine,
(-)-pentazocine, haloperidol, 1,3-di-o-tolylguanidine (DTG), bovine serum albumin (BSA)
fraction V, sucrose, NaCl, tris(hydroxymethyl)aminomethane (Tris), 1N hydrochloric acid
solution, and glacial acetic acid were purchased from Sigma-Aldrich (St. Louis, MO). Coomassie
Protein Assay reagent, Ecoscint scintillation fluid and Brandel GF/B filter papers, 2.25 x 12.25
inches were purchased from Fisher Scientific (Pittsburgh, PA).
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2.3.2 Synthesis of [3H]SN56
The design strategy for generating [3H]SN56 involved replacing a bromine atom on the aromatic
ring of SN56 with a tritium atom (Figure 1). The precursor compounds for the synthesis of
[3H]SN56, compounds 1, 2, 3 and 4 were synthesized by Christophe Mesangeau in the laboratory
of Christopher McCurdy at the University of Mississippi. The preparation of the brominated
precursor 4 is described below. Compounds 1 and 2 were prepared according to previously
described procedures with minor modifications [17, 18]. Selective bromination of the 6propylbenzo[d]thiazol-2(3H)-one 2 at the C-4 position was effected with bromine in acetic acid
at

room

temperature

(RT).

(hexamethyleneimino)ethylchloride

The
in

bromo
the

derivative

presence

of

was

alkylated

potassium

with

2-

carbonate

in

dimethylformamide (DMF) to yield 4. Compound 4 was radiolabeled with tritium (30 Ci/mmol)
by AmBios Labs, Inc. (Newington, CT).

2.3.3 6-Propionylbenzo[d]thiazol-2(3H)-one (1)
Dimethylformamide (5.96 ml, 76.73 mmol) was added slowly to aluminum chloride (35.5 g,
264.6 mmol) with vigorous stirring. After 15 min, 2-hydroxybenzothiazole (5.4 g, 40 mmol) was
added and the mixture was heated to 45 C. After 15 min, propionyl chloride (3.46 ml, 39.7
mmol) was added and the reaction mixture was heated to 85 C for 3 h. The hot mixture was
then poured on ice; the crude product was collected by filtration, and washed with water. The
solid was dissolved in ethyl acetate and the solvent was washed with water and brine, dried and
evaporated. The residue was recrystallized from toluene/dioxane (2/1) to give 2.96 g (54%) of 6propionylbenzo[d]thiazol-2(3H)-one as a white solid. 1H NMR (DMSO-d6):

12.23 (br s, 1H),

8.20 (s, 1H), 7.87 (d, J = 8.4 Hz, 1H), 7.17 (d, J = 8.3 Hz, 1H), 2.97 (q, J = 7.1 Hz, 2H), 1.06 (t, J
= 7.1 Hz, 3H). 13C NMR (DMSO-d6):

198.64, 170.46, 140.13, 131.21, 126.74, 123.69,

123.04, 111.17, 30.93, 8.22. MS (ESI) m/z 206 (M+-1).

2.3.4 6-Propylbenzo[d]thiazol-2(3H)-one (2)
Triethylsilane (4.75 ml, 29.75 mmol) was added to a stirred solution of 1 (2.5 g, 12.06 mmol) in
trifluoroacetic acid (13 ml). The mixture was stirred vigorously for 2 h at RT. The trifluoroacetic
acid was removed by evaporation and the residue was purified by chromatography on a silica gel
column using petroleum ether/ethyl acetate (9:1) as the eluent to give 2.06 g (88%) of 623

propylbenzo[d]thiazol-2(3H)-one as a white solid. 1H NMR (DMSO-d6):

11.76 (br s, 1H),

7.33 (s, 1H), 7.05 (d, J = 8.1 Hz, 1H), 6.99 (d, J = 8.1 Hz, 1H), 2.50 (t, J = 7.4 Hz, 2H), 1.56-1.50
(m, 2H), 0.84 (t, J = 7.3 Hz, 3H). 13C NMR (DMSO-d6):

169.99, 136.68, 134.23, 126.57,

123.24, 122.12, 111.22, 36.87, 24.30, 13.54. MS (ESI) m/z 194 (M++1).

2.3.5 4-Bromo-6-propylbenzo[d]thiazol-2(3H)-one (3)
Bromine (0.45 ml, 8.75 mmol) was added slowly to a solution of 2 (1.5 g, 7.76 mmol) in acetic
acid (10 ml). The mixture was stirred 15 h at RT, poured into water and extracted with ethyl
acetate (3

30 ml). The combined organic layers were washed with a 10% solution of potassium

carbonate followed by brine. The solution was dried over sodium sulfate and evaporated under
vacuum. The residue was purified by chromatography on a silica gel column using petroleum
ether/ethyl acetate (9:1) as the eluent to give 0.5 g (24%) of 4-bromo-6-propylbenzo[d]thiazol2(3H)-one as a white solid. 1H NMR (CDCl3):

9.29 (s, 1H), 7.26 (s, 1H), 7.12 (s, 1H), 2.56 (t,

J = 7.6 Hz, 2H), 1.62 (m, 2H), 0.93 (t, J = 7.2 Hz, 2H). 13C NMR (CDCl3):

170.45, 139.35,

132.22, 129.34, 124.44, 121.24, 103.90, 37.37, 24.48, 13.54. MS (ESI) m/z 270 (M+-1), 272
(M++1).

2.3.6 3-(2-(Azepan-1-yl)ethyl)-4-bromo-6-propylbenzo[d]thiazol-2(3H)-one hydrochloride (4)
NaHCO3 (0.51 g, 6.09 mmol) and 2-(hexamethyleneimino)ethylchloride hydrochloride (0.80 g,
4.06 mmol) were added, with mechanical stirring, to a solution of 3 (0.55 g, 2.03 mmol) in
anhydrous DMF (15 ml). The reaction mixture was heated to 80 C for 1 h. After cooling, the
mixture was poured into 80 ml of water, extracted with ethyl acetate (3

60 ml), and the

combined organic layers were washed with brine and dried. The solvent was removed in vacuo,
and the residue was chromatographed on a silica gel column using ethyl acetate/petroleum ether
(4:6) as the eluent. 3-(2-(Azepan-1-yl)ethyl)-4-bromo-6-propylbenzo[d]thiazol-2(3H)-one was
isolated as a hydrochloride salt (white solid, 0.44 g, 49%) by addition of HCl/dioxane. 1H NMR
(DMSO-d6):

10.81 (br s, 1H), 7.60 (s, 1H), 7.46 (s, 1H), 4.72 (t, J = 7.2 Hz, 2H), 3.47-3.24

(m, 6H), 2.56 (t, J = 7.5 Hz, 2H), 1.86 (br s, 4H), 1.67-1.55 (m, 6H), 0.88 (t, J = 7.2 Hz, 3H).
13C NMR (DMSO-d6):

170.54, 138.87, 132.87, 132.63, 125.62, 121.79, 103.79, 56.73, 55.89,

43.14, 37.04, 28.58, 27.22, 24.51, 13.81. Analysis calculated for C18H26 BrClN2OS: C, 49.83;
H, 6.04; N, 6.46. Found: C, 50.06; H, 5.93; N, 6.47. HRMS calculated for C18H26N2OSBr
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[M+H]+ 397.0949, found 397.0945. A synopsis of the synthetic route of the synthesis of the
brominated [3H]-SN56 precursor is provided in Figure 2.

2.3.7 Membrane preparation
Crude P2 rat brain homogenates were prepared from male, Sprague Dawley rats (150-200 g)
purchased from Harlan (Indianapolis, IN) as described previously [19]. All procedures involving
live animals were performed as approved by the Institutional Animal Care and Use Committee at
the locations where the assays were performed. Briefly, unanesthetized rats were sacrificed by
decapitation; brains minus cerebellum were harvested and maintained in ice cold 10 mM
Tris/0.9% NaCl until processed. Tissues were homogenized with a Potter-Elvehjem homogenizer
(5-10 strokes with motor driven Teflon pestle) in ice-cold 10 mM Tris-sucrose buffer (0.32 M
sucrose in 10 mM Tris, pH 7.4) using 10 ml buffer per g of tissue x ~3 g tissue/batch.
Homogenates from multiple batches were combined and centrifuged for 10 min at 1,000 x g, at 4
°C. Supernatants were decanted, combined and centrifuged for 15 min at 31,000 x g, at 4 °C. The
material from centrifugation at 31,000 x g was washed as follows: 1) pellets were re-suspended
in 10 mM Tris, pH 7.4 using 3 ml buffer per gram of tissue, 2) the resulting suspension was
incubated for 30 min at 25 °C, 3) the resulting suspension was centrifuged for 15 min at 31,000 x
g, at 4 °C. The resulting pellets were re-suspended in Tris, pH 7.4 buffer at a final concentration
of 1 g of tissue per 1.53 ml buffer. Tissue preparations were aliquoted in 1 ml portions and stored
at -80 °C. The Bradford assay was used to quantitate protein concentration [20].

2.3.8 Radioligand binding assays
Initial optimization of assay conditions was performed to maximize total binding and minimize
non-specific binding. Parameters examined included evaluation of the buffer composition and
pH, ratio of radioligand to membrane concentration, and determination of ligand and ligand
concentration for defining non-specific binding. The following optimized conditions were used
for subsequent studies reported below: 0.5 ml final sample volume, 90 min sample incubation at
25 ºC, Tris, pH 8.0 (assay buffer), and 100 µM haloperidol (to define non-specific binding).
Assay termination was effected by vacuum filtration through glass fiber filters on a 24 position
Brandel cell harvester. Prior to use, filters were presoaked for 30 min in 0.5% polyethyleneimine
to reduce non-specific binding. Following the initial filtration step, filters were washed 3 times
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with 5 ml ice-cold 10 mM Tris, pH 8. The conditions determined from the preliminary studies
were consistent with those reported in the literature for the analysis of σ1 receptor binding using
[3H](+)-pentazocine [15, 21, 22]. It should be noted that it was necessary to prepare [ 3H]SN56
spiking solutions in 1 mM HCl, to prevent non-specific binding of the radioligand to glass and
plasticware, which was problematic with solutions prepared in the assay buffer. This requirement
is not unprecedented and the small amount of acid has no impact on the final pH of the assay
sample [23].

2.3.9 Association and dissociation assays
Association and dissociation studies were conducted to confirm that the binding kinetics of
[3H]SN56 were appropriate for a 1-2 h incubation and processing by filtration. Kinetic studies
were performed with 0.8 nM [3H]SN56 and 100 µg membrane. For determination of association
rates, samples were incubated for times ranging from 5 min to 2 h prior to filtration. For
determination of dissociation rates, membranes were incubated for 120 min with [3H]SN56 prior
to the addition of 100 µM (final concentration) haloperidol, followed by filtration at times
ranging from 30 min to 4 h from the addition of haloperidol. The assays were performed in
duplicate and repeated three times.

2.3.10 Saturation binding assays
For the determination of Kd and Bmax by saturation binding, ten concentrations ranging from 0.01
to 0.8 nM of [3H]SN56 were tested per experiment with 100 µg membrane per sample. Nonspecific binding was determined by the addition of haloperidol, at a final concentration of 100
µM. Samples for the determination of total and non-specific binding for each experiment were
run concurrently and filtered simultaneously.

2.3.11 Competition binding assays
For the determination of Ki for established σ ligands by competition binding, aliquots of
membrane were incubated with [3H]SN56 and varying concentrations of test ligands. The
following test compounds were evaluated: 1,3-di-o-tolylguanidine (DTG), haloperidol, (+)pentazocine, (-)-pentazocine and (+)-SKF10,047. For each test compound, ten concentrations
were incubated with 0.7-0.8 nM [3H]SN56 with 100 µg membrane per sample. Non-specific
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binding was determined by the addition of haloperidol, at a final concentration of 100 µM.
Samples for the determination of total and non-specific binding for each experiment were run
concurrently and filtered simultaneously.

2.3.11 Scintillation counting and data analysis
Following washing, filters were transferred to scintillation vials and 5 ml scintillation cocktail
was added. Filters were allowed to soak in cocktail for a minimum of 10 h prior to counting. The
data were analyzed using GraphPad Prism software (San Diego, CA). Saturation binding data
were fit using nonlinear regression to a one-site model. A Hill plot of the saturation data was
generated by linear regression of the plot of log([B]/Bmax-[B]) versus log[L], where [L] =
radioligand concentration, and [B] = the concentration of radioligand bound at the respective [L].
Association kinetics data were fit using linear regression of the plot of ln(Be-B/Be) versus time,
where Be = radioligand bound at equilibrium, and B = radioligand bound at time t; the slope of
the plot yielded kobs. The association rate constant (k+1) was calculated using the pseudo firstorder method from the equation k+1 = (kobs – k-1) / [L]. Dissociation kinetics data were fit using
linear regression of the plot of ln(B/B0) versus time, where B0 = specific radioligand bound at
time of addition of haloperidol, and B = specific radioligand bound at time t. For competition
binding data, Ki values were calculated from experimentally determined IC50 values with the
Cheng-Prusoff equation using the Kd for [3H]SN56 determined from the saturation binding
experiments (0.069 nM). For comparison of competition binding data obtained with [3H]SN56 to
data obtained with [3H](+)-pentazocine a correlation plot was generated with the assumption that
data were sampled from Gaussian populations (Pearson r) using a two-tailed fit.
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2.4 Results

2.4.1 Basic binding parameters
At near saturating conditions, non-specific binding of [3H]SN56 remained essentially constant in
the presence of 25 to 200 µg membrane, suggesting that the observed non-specific binding is due
primarily to filter binding. As shown in Figure 3, total binding was linear from 50 to 200 µg
membrane.

2.4.2 Association and dissociation kinetics
From the association studies, kobs = 0.080 min-1 and k+1 = 9.05x107 min-1M-1. From the
dissociation studies, k-1 = 0.0076 min-1 and t½ = 91 min. The Kd calculated from k-1/k+1 was
0.084 nM. The low dissociation rate permits the use of filtration for the separation of free from
bound radioligand [24], while the association rate supports 90 min incubations for attaining
steady-state binding.

2.4.3 Saturation binding
Figure 4 shows the results of the saturation binding study of [3H]SN56. Non-linear analysis of
the saturation binding data fitted using a one-site model yielded a Kd = 0.069 ± 0.007 nM nM
and a receptor density (Bmax) of 340 ± 10 fmol/mg (R2 = 0.96). This represents a 70-fold higher
affinity than reported for [3H](+)-pentazocine (Kd = 4.8 nM) [15]. A Hill plot of the data yielded
a slope = 1.14 with R2 = 0.96. A two-site fit of the saturation data yielded a “did not converge”
message from the Prism curve-fitting software, indicating the data does not fit a two-site binding
model.

2.4.4 Competition binding
Kis determined in this study using [3H]SN56 versus values determined using rat brain P2 with
[3H](+)-pentazocine, processed using Brandel filtration, determined in studies detailed in Chapter
4 of this dissertation, are shown in Table 1. In Figure 5, a comparison of binding profiles of the
sites labeled by [3H]SN56 versus [3H](+)-pentazocine is shown in a correlation plot of Ki values
obtained in this study versus the values obtained with [3H](+)-pentazocine. For the group of
hallmark sigma ligands tested, there was a significant correlation between the affinities obtained
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using the novel versus conventional radioligand (Pearson r = 0.99). Of particular note is the
higher affinity of (+)-pentazocine as compared to (-)-pentazocine in the assays, a
stereoselectivity pattern that is consistent with binding to σ1 receptors.

2.5 Discussion

Characterization of a series of novel 2(3H)-benzothiazolone compounds in sigma receptor
competition binding assays revealed SN56 (3-(2-(azepan-1-yl)ethyl)-6-propylbenzo[d]thiazol2(3H)-one) to have subnanomolar affinity and >1,000-fold selectivity for the σ1 subtype relative
to σ2 [16]. Binding of SN56 to non-sigma binding sites was tested with a battery of receptors and
transporters including, adrenoceptor α1, adrenoceptor α2, adrenoceptor β1, adrenoceptor β2,
histamine H1, histamine H2, mu opioid, delta opioid, kappa opioid, dopamine D1, dopamine D2,
serotonin 5HT2a, serotonin 5HT3, and GABAA receptors; and dopamine and serotonin
transporters [16]. Of the binding sites tested, only α2 and H1 showed affinities greater than 1 µM
(Ki α2 = 205 nM, and Ki H1 = 311 nM respectively) [16]; however, the affinity of SN56 for the
σ1 receptor is approximately 350-times higher than its affinity for either of these receptors,
indicating a favorable selectivity profile for the development of a radioprobe for use in
radioligand binding studies.
In the present study, [3H]SN56 exhibited >95% specific binding to σ1 receptors in rat brain
membranes at concentrations up to 10 times the Kd. However, non-specific binding of [3H]SN56
to the glass fiber filters used to separate bound from free radioligand was 25-35% at 10 times the
Kd concentration, resulting in a final specific binding signal of 65-75% of total observed binding.
[3H]SN56 exhibited saturable and reversible binding to a single high affinity site in rat P2
membranes with a binding profile similar to that observed for [3H](+)-pentazocine. The Bmax
observed for [3H]SN56 (340 ± 10 fmol/mg) was consistent with the range of values reported in
the literature for rat brain labeled with [3H]BHDP, [3H]SA4503, or [3H](+)-pentazocine [25, 26].
The Hill plot of the saturation binding data, which describes the fraction of receptor saturatation
as of function of radioligand concentration, yielded a slope of 1.14, suggesting there was no
cooperativity in binding of [3H]SN56. In addition, the Ki values of established sigma receptor
ligands determined by competition binding versus [3H]SN56 were consistent with those reported
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in the literature against the well established σ1 radioligand [3H](+)-pentazocine [15].
Furthermore, the association and dissociation kinetics of [3H]SN56 were shown to be amenable
to two hour incubations, and filtration for separation of free from receptor bound radioligand.
Yous et al. [16] reported a Ki of 0.56 nM for SN56 versus [3H](+)-pentazocine in P2 membranes
prepared from guinea-pig brain. Similarly, we obtained a Ki of 0.38 nM versus [3H](+)pentazocine in P2 membranes prepared from rat brain (data not shown). These values are ~5 fold
higher than the affinity determined with saturation and kinetic studies of [3H]SN56 (~0.07 nM
and ~0.08 nM respectively. We suspect that depletion of the non-labeled ligand results in an
erroneously high value for the Ki of SN56 as determined by competition binding.
While most researchers are familiar with radioligand depletion due to excessive receptor
concentration, depletion of the unlabeled ligand occurs when the affinity of the unlabeled
compound greatly exceeds the affinity of the labeled compound [27, 28]. Goldstein et al. [28]
used computer modeling to derive estimates of the error in the determination of the Ki of ligands
exhibiting higher affinities than the radioligands utilized in their measurement; the authors
projected that for an unlabeled ligand with a true affinity 100 times greater than the radioligand
(as in our case), 10% radioligand depletion would result in an experimentally determined Kd ~6
times higher than the true value. Thus, the ~5-fold difference between the affinity of SN56, as
determined by competition binding, and the affinity of [3H]SN56 determined with saturation and
kinetic studies may be explained by this phenomena.

Systematic errors resulting from the use of high receptor concentrations may also contribute to
errors in both the determination of Kd from saturation and kinetic experiments, and in the
determination of Kis of unlabeled compounds. However, these errors are minimal, quantifiable,
and in practice when [3H]SN56 is used for competition binding assays of σ1 ligands, our
preliminary results suggest they have no impact on our Ki determinations as compared to
historical data for the compounds tested

Practical considerations dictated that we use relatively high receptor concentrations; this
introduces systematic error that is quantifiable and within acceptable limits. When possible,
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experimental conditions for binding experiments should be chosen so that the receptor
concentration is less than 10% of the Kd of the radioligand to minimize radioligand depletion
[27]. However, with a radioligand with subnanomolar affinity this would require multi-milliliter
sample volumes. Our experiments required 100 µg of tissue to obtain adequate signal for precise
detection. We chose 0.5 ml sample volumes because we intend to adapt this method to a higher
throughput 96-well method where sample volumes are more limited than in test tube based
binding determinations. To ensure that >90% of added radioligand was “free” (unbound) in
competition binding experiments run under these conditions we utilized high concentrations of
[3H]SN56. While these conditions are not ideal they are tolerated if required for detection and the
error in values obtained with the method are known and within an acceptable range as
determined by the researcher’s requirements [29].

Carter et al. [29] examined the effects of assay miniaturization using the human muscarinic M3
receptor expressed in CHO (Chinese hamster ovary) cells. This cell line expressed the M3
receptor at ~5 pmol/mg, and the novel radioligand they tested, [3H]NMS (1-[N-methyl-3H]
scopolamine methyl chloride), had an affinity of 41 pM [29]. In their saturation binding studies
they varied receptor concentrations over a wide range, with membrane amounts from 5-50 µg in
volumes from 50-1750 µl, resulting in ratios of receptor concentration ([receptor])/Kd from 0.35122 [29]. They found that as the volume was decreased or the amount of membrane was
increased the calculated Kd and Bmax increased [29]. When no corrections were made for
radioligand depletion, with [receptor]/Kd = 0.35 (the lowest ratio tested, corresponding to 5 µg in
1750 µl) they calculated the Kd to be approximately 2.4 times the “true” value and with
[receptor]/Kd = 12.2 (5 µg in 50 µl) they calculated the Kd to be approximately 4.6 times the true
value [29]. When the Kds were recalculated, taking into account radioligand depletion, the
resulting values were 2.3 and 3.0 times the true value, respectively [29]. Therefore, practitioners
should be aware that experimental conditions resulting in excessive radioligand depletion will
yield an overestimate of the true Kd even if depletion is accounted for.
The conditions chosen for our saturation studies utilized a [receptor]/Ki of ~ 0.25. No corrections
were made for radioligand depletion because it was not possible to accurately assess what
portion of non-specific binding was due to binding to membrane versus binding to filter. Based
31

on Carter’s work [29] we might expect our results to overestimate the Kd of [3H]SN56 by ~3fold. Carter’s studies [29] of competition binding utilizing conditions of excessive radioligand
depletion did not model the conditions we utilized, with [receptor] = ~0.1 nM and concentration
[3H]SN56 = ~1.5 times the Ki of SN56, so direct comparisons of our competition binding data to
their data are not possible. However, as stated previously, the Ki values we derived for the sigma
receptor ligands tested correlated well with values reported in the literature.
No significant difference in binding affinities was observed following labeling with [ 3H](+)pentazocine versus [3H]SN56 for the ligands tested. A larger pool of compounds should be
screened to confirm that this relationship is maintained. If compounds are identified that yield
significantly different Kis with [3H](+)-pentazocine versus [3H]SN56, such a result would
suggest that σ1 receptors support multiple binding modalities.

Future advances in the field of sigma receptor therapeutic development will require greater
knowledge of the nature of the interaction of sigma receptors with ligands and protein binding
partners. Additional tools needed to further this knowledge include new subtype-specific agonist
and antagonist ligands, radioligands, and other affinity labels and probes. The development of
other technologies, such as high throughput methods for the determination of binding affinities,
and in vitro functional assays, will also hasten efforts to design and identify new selective sigma
ligands with potential therapeutic value.
In conclusion, the results of our studies show that [3H]SN56 possesses high affinity and
selectivity for the σ1 receptor, and appears to be a viable alternative for [3H](+)-pentazocine in
radioligand binding assays. [3H]SN56 demonstrated saturable and reversible binding to a single
high affinity site in rat brain membranes with a binding profile similar to that observed for
[3H](+)-pentazocine. Thus, [3H]SN56 represents a valuable tool for the study of the σ1 receptor
and the development of σ1 receptor based therapeutics. Additional studies of [3H]-SN56 are
warranted to confirm the results observed in this study and more fully characterize its interaction
with the σ1 receptor. Proposed additional studies include: 1) expanding the number of ligands
tested in competition binding studies with direct comparisons to results obtained with [3H](+)-
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pentazocine, and 2) confirming that SN56 competitively inhibits the binding of [3H](+)pentazocine and that (+)-pentazocine competitively inhibits the binding of [3H]-SN56.
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Figure 1. Structures of SN56, [3H]SN56 and its bromo precursor 4.
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Figure 2. Synthesis of brominated [3H]SN56 precursor 4 : a) Propionyl chloride, AlCl3, 85 C ;
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Figure 3. Binding linearity for [3H]SN56 with rat brain P2 membranes. Samples contained 0.7
nM [3H]SN56, in a total volume of 0.5 ml. Non-specific binding (NSB) was determined by the
addition of 100 µM haloperidol. Data points represent the mean of three independent
determinations of duplicate samples at each membrane concentration. The data point at 300 µg
rat brain P2 deviates from the linear binding observed from 50-200 µg.
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Figure 4. Saturation binding of [3H]SN56 with rat brain P2 membranes. Samples contained 100
µg membrane in a total volume of 0.5 ml. Data points represent the mean ± SEM of three
independent determinations of duplicate samples at each concentration. Bmax = 340 ± 10
fmol/mg, Kd = 0.069 ± 0.007 nM.
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Table 1. Summary of data from competition binding experiments. The Ki values determined
with [3H](+)-pentazocine were obtained using rat brain P2 processed by Brandel filtration as
detailed in Chapter 4 of this dissertation.

Compound

Ki (nM)
[3H]SN56

[3H](+)-pentazocine

Haloperidol

3.5 ± 1.1

3.9 ± 0.5

(+)-pentazocine

5.7 ± 1.0

8.7 ± 0.4

(-)-pentazocine

77.0 ± 9.0

57.2 ± 1.9

DTG

41.6 ± 8.8

57.4 ± 3.3

289 ± 6

287 ± 36

(+)-SKF10,047
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Figure 5. Comparison of Ki values determined with [3H]SN56 versus values determined with
[3H](+)-pentazocine as detailed in Chapter 4 of this dissertation. Pearson r = 0.99. 1, haloperidol;
2, (+)-pentazocine; 3, (-)-pentazocine; 4, DTG; 5, (+)-SKF10,047.
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CHAPTER 3
A 96-well filtration method for radioligand binding
analysis of sigma receptor ligands
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3.1 Abstract

Sigma receptors represent a potential drug target for numerous therapeutic indications including
cancer, depression, psychostimulant abuse, and stroke. To date, no in vitro assays have been
developed which are amenable to routine use for determining the functional activity of novel
sigma ligands. As a result, radioligand binding assays are currently used as a primary screen to
identify promising candidates for in vivo studies. Most published radioligand binding studies for
sigma receptors utilize a low throughput method employing a “cell harvester.” Higher
throughput methods are required to facilitate more efficient screening of the large numbers of
novel compounds our laboratory routinely analyzes for binding to sigma receptors. This study
compared binding affinities determined with a new medium-throughput 96-well filtration method
to results obtained using the conventional cell harvester-based method. The 96-well assay
utilized rat liver membranes for the determination of both known sigma receptor subtypes (σ1
and σ2) because this tissue contains high densities of both subtypes and fulfils criteria required
for reliable use with the 96-well format. The new method was shown to give comparable Ki
values for reference ligands, and a novel series of 2(3H)-benzothiazolone compounds, analyzed
in parallel with samples prepared in rat brain membranes and processed on the traditional cell
harvester. For σ1 receptors equivalent affinity values were observed for both methods/tissues.
For σ2 receptors, approximately 2-fold higher affinities were observed for most compounds in
liver membranes as compared to brain membranes but excellent correlation with brain-derived
values was maintained. Analysis of the 2(3H)-benzothiazolone series identified several new
compounds with nanomolar affinity and greater than 50-fold specificity for σ1 versus σ2
receptors. Further, because dramatic differences in subtype binding were observed in this
synthetic series, this study also provided useful data for the continued development of
pharmacophore models for both sigma receptor subtypes.
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3.2 Introduction

The sigma receptor was first described as an opioid receptor subtype based on the behavioral
effects of N-allylnormetazocine (SKF-10,047) in dogs [1]. Subsequent in vitro radioligand
binding studies revealed that the binding site for prototypic sigma ligands was a protein distinct
from opioid receptors [2, 3]. Currently, two subtypes of sigma receptors are recognized, σ1 and
σ2; these subtypes can be distinguished by differences in ligand selectivity, tissue distribution
and molecular properties. Because sigma receptors are recognized as potential therapeutic and
radioprobe targets, research to ascribe in vitro and in vivo activities to the respective subtypes is
a major focus of sigma receptor research [4-8]. Consequently, to facilitate these studies, efforts
to synthesize and identify novel subtype selective agonist and antagonist compounds are
ongoing.

There are currently no accepted in vitro assays for routinely testing sigma receptor ligand
activities; therefore, radioligand binding serves a critical role in screening novel ligands.
Radioligand competition binding assays using a conventional cell harvester represent a
bottleneck in the development of new sigma ligands due to the low throughput nature of the
format. 96-well filtration offers the potential to increase throughput and reduce costs for routine
radioligand binding assays.

Previous reports of the use of 96 well filtration methodologies for the analysis of sigma receptor
binding are limited to two research groups [9-14]. The Mach group from Washington University
were the first to report the use of 96-well filter plates for the analysis of sigma receptor binding
[11]. In these initial studies binding to σ2 receptors in crude rat liver homogenate, and in human
and mouse tumor xenografts was examined with [3H]DTG and a novel σ2 specific radioprobe,
[3H]RHM-1

(N-[4-(3,4-dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)butyl]-2-methoxy-5-met

hyl-benzamide). Later studies extended the technique to the determination of σ1 affinities in
guinea-pig brain membranes labeled with [3H](+)-pentazocine [9, 13, 14]. A more recent study
reported by the Wünsch group from the University of Münster examined binding at both sigma
subtypes utilizing “filtermats,” an alternative filter format designed for 96-well use [10]. The
results of these studies suggested that 96-well filtration is a viable approach for separation of free
45

from receptor bound radioligand for sigma receptor binding studies. However, to support future
routine use of the 96-well filtration based process, additional confirmation that results obtained
using the method produces results equivalent to the more established cell harvester-based
methods is needed.

The majority of contemporary sigma receptor binding studies are performed with P2 membranes
prepared from guinea-pig brain for assaying σ1 receptor binding, and rat liver P2 membranes for
assaying σ2 receptors, because these tissues are enriched in the respective subtypes [9, 10, 15,
16]. Reported values for Bmax of σ1 in rodent brain P2 vary, ranging from approximately 300 to
500 fmol/mg for rat brain [17, 18], and approximately 575 fmol/mg to 2.0 pmol/mg, for guineapig brain [19-22]. The published Bmax value for σ2 receptors in rat liver P2 is ~9 pmol/mg [23].
Receptor expression levels of 2 pmol/mg or greater are required for detection with tritiated
ligands and the typical sample sizes of 2-100 µg total protein per well used in 96-well filtration
assays [24-26]. This requirement is due to the limited filtration capacity of 96-well filter plates
and the relatively low specific activity of tritium. Because the reported expression level for σ1
receptors in guinea-pig brain varies and the highest reported level of 2.0 pmol/mg [19] just meets
the minimum criteria for processing by 96-well filtration we sought a tissue with greater σ1
receptor expression levels.

Rat liver P2 contains high densities of both subtypes of sigma receptors [23, 27, 28];
representative Bmax values determined for σ1 and σ2 are ~3 pmol/mg and ~9 pmol/mg
respectively [23]. It has also been reported that rat brain and rat liver homogenates yield similar
affinity values for binding of σ1 reference ligands [28-30], and as stated previously, rat liver is
already the established preferred tissue for σ2 binding studies [31]. Rat liver was thus chosen for
development of this assay.
Despite the reported equivalency of rat liver and rat brain membranes for the determination of σ1
binding [28-30] it was necessary to rigorously demonstrate that the two tissues would yield
similar results in our hands using the 96-well filtration platform. Uncharacterized differences in
lipid composition, protein partners, and cellular distributions of σ1 in P2 isolates of the two
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tissues may introduce unanticipated artifacts that impact affinity measurements. Known
differences in lipid compositions of whole organ homogenates of rat liver compared to rat brain
include: 1) higher amounts of phosphatidylcholine in liver, 2) higher amounts of
phosphatidylethanolamine in brain, and 3) the presence of cerebrosides and sulfatides in brain
that are not found in liver [32]. The relative distribution of these lipids in P2 membranes isolated
by our methods has not been reported; therefore, it is not known if the differences observed in
whole tissue homogenates are reflected in this fraction.
Determinations of σ2 binding may also be influenced by differences in lipid composition or
protein partners in the two tissues. Because σ2 receptors reside in lipid rafts, and behave very
differently to detergent extraction relative to σ1 receptors [33, 34], lipid composition differences
in the two tissues may be an important consideration. Despite the continued use of brain tissues
by some researchers for the determination of σ2 receptor binding affinities [35-38], there have
been no rigorous comparisons of binding at σ2 in brain versus liver membranes. Furthermore, it
has not been conclusively established that σ2 receptors present in the brain are the same protein
as those found in liver.

Extending on earlier work by Ucar et al. [39], Yous et al. [40] reported a structure-binding
affinity study for a small series of benzothiazolone compounds with high affinity and specificity
for sigma receptors. In this study they identified SN56 (3-(2-(azepan-1-yl)ethyl)-6propylbenzo[d]thiazol-2(3H)-one) as a new sigma receptor specific ligand with nanomolar
affinity and unprecedented selectivity for the σ1 versus the σ2 subtype and versus a battery of
non-sigma receptors and neurotransmitter transporters [40]. More recent in vivo and in vitro data
suggested SN56 as a promising lead compound for further investigations of additional 2(3H)benzothiazolone analogues [41]. We have shown that [3H]SN56 yields a similar pharmacological
profile compared to the universally accepted σ1 radioprobe, [3H](+)-pentazocine [41].
Additionally, behavioral studies performed in our laboratory demonstrated that SN56 protected
mice against cocaine-induced convulsions (unpublished data), similar to other established σ1
antagonists [42-45].
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In the present report, in addition to a series of reference compounds, a series of novel 2(3H)benzothiazolone compounds were analyzed for binding to sigma receptors to validate the method
for routine use. The reference compounds used in this study represent known sigma ligands with
well-established pharmacological characteristics. The 2(3H)-benzothiazolone compounds
examined included variations in: 1) the size of the attached heterocycle, 2) the heterocycle linker
chain length, and 3) the composition of the alkyl or acyl chain at position 6 of the 2(3H)benzothiazolone system. Following successful demonstration that the proposed 96-well method
gave satisfactory results with the reference compounds, the binding affinities of the 2(3H)benzothiazolone compounds for sigma receptors were determined.

Because radioligand binding assays serve a significant role in identifying new sigma ligands and
current methods do not meet our current throughput needs, we sought to develop a higher
throughput method. We chose to examine a 96-well filtration format and evaluated the procedure
with reference ligands and analogues of the 2(3H)-benzothiazolone compound, SN56. The
method employed rat liver membranes for the determination of binding at both σ1 and σ2
receptors. Binding affinities determined with this new method were compared to measurements
generated using conventional filtration to qualify the validity of this new approach for routine
screening of novel sigma ligands.

3.3 Materials and Methods

3.3.1 Chemicals and Reagents
[3H](+)-Pentazocine (specific activity = 29 Ci/mmol) and [3H]DTG (specific activity = 53.3
Ci/mmol) were purchased from Perkin Elmer (Boston, MS). (+)-Pentazocine, (-)-pentazocine,
(+)-N-allylnormetazocine

hydrochloride,

1,3-di-o-tolylguanidine

(DTG),

haloperidol,

progesterone, dextromethorphan hydrobromide, rimcazole dihydrochloride monohydrate,
sucrose, NaCl, dimethylsulfoxide (DMSO) and tris(hydroxymethyl)aminomethane (Tris), were
purchased from Sigma-Aldrich (St. Louis, MO). NE100 (4-methoxy-3-(2-phenylethoxy)-N,Ndipropylbenzeneethanamine

hydrochloride),

BD1063

(1-[2-(3,4-dichlorophenyl)ethyl]-4-

methylpiperazine dihydrochloride), and fluvoxamine maleate were obtained from Tocris
Bioscience (Ellisville, MO). AC927 (N-phenethylpiperidine oxalate) was provided by Dr.
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Andrew Coop from the University of Maryland (Baltimore, MD). SN56 (3-(2-(azepan-1yl)ethyl)-6-propylbenzo[d]thiazol-2(3H)-one) and the RB compound series (see Table 2) were
provided by the laboratory of Dr. Christopher McCurdy from the University of Mississippi
(University, MS). Coomassie Protein Assay reagent, 1N hydrochloric acid, glacial acetic acid,
Ecoscint, Microscint 20, Brandel GF/B filter papers, 2.25 x 12.25 inches, and Unifilter-96 GF/B
filter plates were purchased from Fisher Scientific (Pittsburgh, PA).

3.3.2 Membrane preparation
Rat brain P2 and rat liver P2 fractions were prepared as described previously and outlined below
from frozen tissues obtained from Pel-Freeze (Rogers, AR) [46]. Tissues were homogenized
batch-wise with a Potter-Elvehjem homogenizer (5-10 strokes with motor driven Teflon pestle)
in ice-cold 10 mM Tris-sucrose buffer (0.32 M sucrose in 10 mM Tris, pH 7.4) using 10 ml
buffer per g of tissue with ~3 g of tissue per batch. Homogenates from multiple batches were
combined and centrifuged for 10 min at 1,000 x g, at 4 °C. Supernatants were decanted,
combined and centrifuged for 15 min at 31,000 x g, 4 °C. To reduce levels of bound endogenous
ligand(s) the resulting P2 membrane was washed as follows: 1) pellets were re-suspended in 10
mM Tris, pH 7.4 using 3 ml buffer per g of wet tissue, 2) the resulting suspension was incubated
for 30 min at 25 °C, 3) following incubation, the suspension was centrifuged for 15 min at
31,000 x g, at 4 °C. The resulting pellets were re-suspended in 10 mM Tris, pH 7.4 buffer at a
final concentration of 1 g starting tissue weight/1.5 ml. Tissue preparations were aliquoted in 1
ml portions and stored at -80 °C. The Bradford assay was used to quantitate protein
concentration (Bradford, 1976).

3.3.3 96-well filtration with rat brain membrane
The 96-well filtration method was tested with rat brain P2 membranes to confirm that this
material was incompatible with processing using the 96-well filtration plates. Samples were
prepared and processed as described below for competition binding assays of rat liver processed
by 96-well filtration except samples contained 25, 50 or 100 µg/well rat brain P2 membrane
instead of rat liver P2 membrane. Each membrane concentration was assayed in triplicate for
total and non-specific binding. Full sample plates containing 100 and 200 µg/well were also
prepared and processed to confirm that the results of the samples described above were not
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compromised by loss of vacuum pressure due to the use of varied membrane concentrations in
individual test wells. These samples were prepared in a total volume of 0.5 mL/well to more
faithfully duplicate typical samples prepared for filtration using the Brandel harvester.

3.3.4 Binding linearity with rat liver membranes processed by 96-well filtration
To determine the appropriate amount of rat liver membrane to use in competition binding assays
processed by 96-well filtration, binding linearity studies were performed for both sigma receptor
subtypes. Samples were prepared and processed as described below for competition binding
assays. Samples contained 0, 10, 20, 30, 40, 50, or 60 µg/well rat liver membrane. Each
membrane concentration was assayed in triplicate for total and non-specific binding.

3.3.5 Competition binding assays
To test the suitability of the 96-well filtration method for routine use in determining sigma ligand
binding affinities, a series of sigma reference ligands were assayed using the 96-well method and
re-assayed using the conventional cell harvester-based method. Following successful
demonstration of the correlation between the two processes, a series of 2(3H)-benzothiazolone
compounds were assayed with the 96-well filtration method.

Radioligand binding assays utilized optimized buffer and incubation conditions that are
consistent with those reported in the literature for the analysis of sigma receptor binding [20, 23,
47]. Stock solutions of test ligands were prepared in DMSO or deionized water at 5 or 25 mM.
Dilutions of reference ligands for competition studies were made with assay buffer (50 mM Tris,
pH 8). Dilutions of 2(3H)-benzothiazolone analogues were prepared in 1 mM HCl. The use of 1
mM HCl for dilution of 2(3H)-benzothiazolone analogues was required to reduce binding of
these compounds to glass tubes or polypropylene microplates and had no effect on the final pH
of the samples or on total binding relative to samples prepared in assay buffer alone (data not
shown). For samples requiring DMSO for solubilization, a final concentration of up to 1-2%
DMSO in assay samples had no effect on total binding.

Assays with rat brain were processed using a Brandel R48 harvester (Gaithersburg, MD), and
assays with rat liver were processed using a Connectorate 96-well harvester (Dietikon,
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Switzerland). For compounds assayed with brain homogenate, 400 µg of rat brain P2 membrane
was added to a glass test tube containing test ligand and radioligand in assay buffer in a final
volume of 0.5 ml. For compounds analyzed with rat liver homogenate, 40 µg of rat liver P2
membrane was added to a polypropylene plate (catalogue number 07-200-697, Fisher Scientific)
containing test ligand and radioligand in assay buffer in a total volume of 0.25 ml.
Assays for σ1 receptors used a final concentration of 5 nM [3H](+)-pentazocine. Labeling of σ2
was effected with either 3 nM [3H]DTG for brain membranes, or 5 nM [3H]DTG for liver
membranes; these samples also contained 300 nM (+)-pentazocine (to block σ1 receptors). The
concentrations of radioligand stock solutions were calculated based on CPM measurements and
specific activities reported by the manufacturer. Nonspecific binding (NSB) was determined by
the addition of haloperidol to a final concentration of 10 µM. Samples were incubated for 120
min at 25°C for all assays. Samples prepared in test tubes and processed with the Brandel
harvester were vortexed prior to incubation; samples prepared in microplates for 96-well
filtration were agitated during incubation on a 96-well plate shaker. Following incubation,
samples were filtered and washed. Samples processed on the Brandel cell harvester were washed
3 times with 3 ml of 10 mM Tris, pH 8. Samples processed by 96-well filtration were washed 5
times with 0.2 ml of 10 mM Tris, pH 8. Prior to use GF/B filter papers and Unifilter GF/B filter
plates were soaked in 0.5% polyethyleneimine (PEI) for 30 min to reduce non-specific binding.

For the determination of binding affinities, each test compound was assayed at 11 concentrations
varying from 0.001 – 10 µM. Samples were prepared and processed in duplicate for each binding
curve and triplicate determinations of binding curves were made for each compound. Samples
for the determination of total and non-specific binding for each experiment were run
concurrently and filtered simultaneously. Following washing, filters processed on the Brandel
harvester were transferred to scintillation vials and 3 ml scintillation cocktail was added to each
sample. Filters were allowed to soak in cocktail for a minimum of 10 h prior to counting on a
Beckman LS6500 scintillation counter (Brea, CA). Samples processed by 96-well filtration were
counted on a Perkin Elmer Microbeta2 2450 microplate counter (Waltham, MA), in the Unifilter
plates, following a 2 h incubation at room temperature with 40 µl Microscint-20 cocktail per
well.
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3.3.6 Data analysis
The competition binding data were analyzed with GraphPad Prism software (San Diego, CA)
using a one-site nonlinear regression model to determine the concentration of ligand that inhibits
50% of the specific binding of the radioligand (IC50 value). Ki values were calculated from the
IC50 using the Cheng-Prusoff equation [48]. To compare binding data from conventional binding
experiments to the 96-well filtration method, correlation plots were generated with GraphPad
Prism, using a two-tailed fit with the assumption that data were sampled from Gaussian
populations (Pearson r). For comparison of individual Ki values obtained using rat liver versus
rat brain a two-tailed t-test was performed using InStat software (San Diego, CA). Hill plots of
competition binding data were determined with GraphPad Prism software using the "sigmoid
dose-response (variable slope)" equation. Partition coefficients adjusted for pH (logD) were
calculated using ACD Labs, I-Lab 2.0 (v5.0.0.184, Toronto, Ontario, Canada).

3.4 Results

3.4.1 96-well filtration with rat brain membrane
Samples of rat brain membrane were prepared and processed using the 96-well filtration format
to confirm that this material did not contain high enough expression levels of σ1 receptors to be
compatible with analysis by this method. Percent non-specific binding (% NSB) for 0, 25, 50 and
100 µg membrane/well was 93%, 92%, 76% and 59% respectively. Wells containing 100 µg
membrane/well appeared to clog as evidenced by incomplete emptying of wash solution from the
sample plate. The full plates prepared with 100 or 200 µg membrane/well also appeared to clog
with membrane; despite the appearance that the samples transferred to the filters, washing was
not possible.

3.4.2 Binding linearity with rat liver membranes
To determine the appropriate amount of rat liver P2 membrane to use in competition assays with
96-well filtration, a binding linearity study was performed for both receptor subtypes using
conditions optimized from preliminary experiments. Figures 1 and 2 show that binding of both
[3H](+)-pentazocine and [3H]DTG (in the presence of 300 nM (+)-pentazocine) increased
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linearly from 0 to 50 µg rat liver P2 membrane (total protein) added per well. Non-specific
binding also increased linearly and remained a constant percent of total binding throughout the
linear range of total binding. For σ1 receptors non-specific binding was 15-20% of total binding;
for σ2 receptors, non-specific binding was 10-15% of total binding. For σ2 binding assays a
titration experiment confirmed that 300 nM (+)-pentazocine was sufficient to adequately block
σ1 receptors without significantly impacting σ2 binding. Based on these results competition
binding studies for all compounds analyzed by 96-well filtration utilized 40 µg liver membrane
per well. This amount of membrane ensured that <10% of added radioligand bound to sigma
receptors (in this case radioligand binding was <3-4% of added label), a requirement for
application of competition binding algorithms based on the laws of mass action [49]. Nonspecific binding for samples prepared with rat brain and processed with the Brandel harvester
averaged 40-50% for σ1 receptors and 30-40% for σ2 receptors.

3.4.3 Binding affinities of reference ligands
Sigma receptor binding affinities for individual reference compounds as reported in the literature
and as determined in this study are shown in Table 2 and Table 3, for σ1 and σ2 receptors
respectively. Overall, values obtained for sigma binding in rat brain P2 from this study were
similar to values reported in the literature, where measurements were made with similar
experimental conditions in either rat or guinea-pig brain fractions (see legend to Table 2).
Likewise, similar σ1 binding affinities were observed for samples analyzed in this study with
liver P2 versus brain P2 for all reference compounds with the exception of those compounds
with low affinity: progesterone, dextromethorphan and rimcazole; these compounds showed
statistically significant higher affinities in liver as compared to brain (progesterone, P < 0.001;
dextromethorphan, P < 0.005; rimcazole, P < 0.001). At σ2 receptors, all compounds tested
showed higher affinity in liver versus brain, with most compounds displaying an approximately
2-fold higher affinity in liver compared to brain; the difference was statistically significant, for
six of the ten compounds tested (DTG, P < 0.005; haloperidol, P < 0.001; NE100, P < 0.001;
BD1063, P < 0.001; AC927, P < 0.005; and fluvoxamine, P < 0.005). Figure 3A shows
correlation plots for σ1 binding in rat liver P2 versus rat brain P2 as determined in this study
(Pearson r = 0.97), and Figure 3B shows binding in rat brain P2 versus literature values for rat or
guinea-pig brain membranes (Pearson r = 0.95). Figure 4A shows a correlation plot for σ2
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binding in rat liver P2 versus rat brain P2 as determined in this study (Pearson r = 0.98), and
Figure 3B shows binding in rat brain P2 versus literature values for rat or guinea-pig membranes
(Pearson r = 0.95). Pearson r values for these plots indicate that binding is proportional over a
four log range of Ki values for σ1 receptors and an approximately two and a half log range for σ2
receptors in rat liver P2 versus rat brain P2.

3.4.4 Binding affinities of 2(3H)-benzothiazolone analogues
Sigma receptor binding affinities determined in this study for individual test compounds are
shown in Table 4. The parent compound structure is shown in Figure 5 where R represents the
appended alkyl or ketonyl chain, m represents ring size, and n represents linker chain length.
Some general trends observed include: 1) a reversal in selectivity from σ1 to σ2, for azepine ring
compounds (m = 2) with increasing linker arm length (from n = 2 to n = 5), reflecting marginal
changes in affinity at σ1 and significant increases in affinities for the σ2 subtype, 2) reduced
affinity for both sigma subtypes when the azepine ring of SN56 was replaced with a pyrrolidine
ring (m = 0), as demonstrated by RB65 and RB75, and 3) a dramatic decrease in σ2 affinity with
a marginal change in σ1 affinity for linker length n = 1, with an azepine ring, and a change of the
chain at position 6 from (CH2)2CH3 to COCH2CH3, as demonstrated by SN56 and RB74. The Ki
σ2/Ki σ1 value of 483 for RB74 versus 168 for SN56 represents an approximately 3-fold
improvement in σ1 selectivity, primarily due to an almost 8-fold decrease in affinity at σ2 for
RB74 versus SN56.

3.4.5 Pseudo-Hill coefficients for competition binding curves
Pseudo-Hill coefficients (pseudo-nH) were calculated to determine if the competition binding
data was consistent with a reversible bimolecular interaction following the laws of mass action
[50, 51]. No samples yielded a pseudo-Hill coefficient significantly different from unity; no
deviations greater than 0.15 were observed. Where a sample deviated greater than 0.1 from unity
visual inspection of the curve overlaid with a curve generated with the slope constrained to unity
suggested the calculated value was anomalous. Because the pseudo-Hill coefficient describes the
equilibrium between both the labeled and unlabeled compounds with the receptor, small
deviations can be expected [50, 51].
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3.4.6 Binding affinity versus lipophilicity for 2(3H)-benzothiazolone analogues
To determine if there was a correlation between the lipophilicity of the appended R group at
position 6 on the 2(3H)-benzothiazolone base structure, and binding affinity among homologues
with similar linker chain lengths, a plot of log Ki versus logD was generated. LogD was
calculated using ACD Labs software and are tabulated for pH = 8 because this was the pH used
for the binding determinations. The results for all compounds are shown in Table 7. The plot of
log Ki versus logD for the homologous compounds is shown in Figure 6. For n=2 a change in the
R group from H to (CH2)2CH3 resulted in a change in logD from 1.52 to 2.82 with a concomitant
10-fold increase in affinity at σ2. Similarly for n=3 the change from H to (CH2)2CH3 resulted in a
change in logD from 1.47 to 2.60 with a concomitant 23.5-fold increase in affinity at σ2. For n=2
a change from (CH2)2CH3 to (CH2)3CH3 resulted in a change in logD from 2.82 to 3.14 that
resulted in almost no change in affinity from Ki = 17.2 to 15.3 nM. A similar effect was observed
with the n=3 compounds. For n=4 and n=5 the transition from H to (CH2)2CH3 to (CH2)3CH3
resulted in significant increases in log P with insignificant changes in Ki. When the R group was
changed from COCH2CH3 to CO(CH2)2CH3 insignificant changes were observed in Ki with an
increase of logD from 2.23 to 2.72 for n=2, 2.16 to 2.25 for n=3, 1.7 to 2.47 for n=4 and 2.37 to
2.67 for n=5.
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3.5 Discussion

In this study a 96-well method for radioligand competition binding was evaluated for routine use
in the determination of sigma ligand binding affinities. The results for binding of reference
ligands to rat liver P2 membranes analyzed with the 96-well method demonstrated excellent
correlation with values derived in rat brain P2 membranes assayed using the conventional
Brandel-based method, for both σ1 and σ2 receptor subtypes. These results suggest that 96-well
filtration is a suitable alternative to Brandel filtration for the analysis of sigma receptor
radioligand binding. Application of the assay to the analysis of a novel series of 2(3H)benzothiazolone compounds identified several new σ1 selective analogues and provided
structure-binding affinity data that distinguish structural features which confer subtype
selectivity for this compound class. Our data also showed that σ2 receptors derived from rat liver
P2 appear to exhibit higher affinity for sigma ligands than those isolated from rat brain P2, a
result that has not been previously reported. The source of this difference is unknown but should
be considered when comparing relative binding to σ1 versus σ2 receptors where binding
determinations are made in homogenates from different tissues.

The 96-well method detailed here is an adaptation of the approach commonly described in the
literature for analysis of sigma receptor competition binding, where typical studies utilized a
Brandel “cell harvester” for separation of free from bound radioligand. Conversion of the method
to a 96-well format was proposed to facilitate greater throughput in our routine sigma receptor
binding screens of new putative sigma ligands. Adaptation of the conventional method for
radioligand binding assays of σ1 receptors to the 96-well method required the use of rat liver
membranes instead of the more commonly used rat or guinea-pig brain derived P2 membranes.
This requirement was necessitated by filtration capacity limitations imposed by the 96-well filter
configuration as well as additional considerations related to improving reproducibility for
medium throughput screening as discussed below.
.
Our studies with rat brain membranes processed by 96-well filtration indicated that 100 µg of rat
brain P2/sample well resulted in clogging of the 96-well filterplates, and lower amounts of
membrane did not generate adequate signal for reliable measurements. In contrast, the 96-well
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assay using rat liver membranes only required 40 µg of membrane to achieve adequate signal,
and >60-80 µg resulted in radioligand depletion. We did not test guinea-pig brain P2 because
reported values of σ1 expression in this tissue were variable and the highest reported value of 2
pmol/mg [21] just met the minimum criteria for use with tritiated radioligands and the sample
size limitations imposed by the 96-well filterplates. Additionally, as outlined below it was our
desire to utilize one tissue for assaying both receptor subtypes and neither guinea-pig nor rat
brain contain adequate levels of σ2 receptors to support this goal.
We did not observe significant differences in binding affinities for σ1 receptors between the two
assay methods for the majority of reference ligands tested. Because the σ1 receptor protein
appears well conserved among species and there is no evidence for differences in the protein in
brain versus liver, the choice of liver as a source of σ1 receptors was not expected to greatly
impact affinity measurements [28, 52-56]. Moreover, binding studies with different crude
membrane preparations, sub-cellular fractions and solubilized extracts derived from brain and
liver from rat and guinea-pig, indicate that affinities of ligands for σ1 remain essentially constant
despite the varied sources of receptors [23, 27-30, 57-59]. However, the cell biology of sigma
receptors is still being elucidated and previously undetected differences may exist so a
systematic comparison was needed. The observation that the low affinity compounds,
progesterone, dextromethorphan and rimcazole, showed statistically significant higher binding
affinities in liver membranes versus brain membranes is in agreement with previous observations
reported by Klouz et al. [29, 30]; however, the source of this difference is unknown.
Our observation that most of the reference ligands tested bound with higher affinity to σ2
receptors isolated from liver compared to brain was unexpected. The differences were
statistically significant for six of the ten compounds tested. While conclusive evidence for the
source of the observed differences is lacking, we propose three possible factors that may
contribute to ligands showing higher affinity in liver relative to brain: 1) differences in lipid
and/or protein partners associated with σ2 in the two organ isolates, 2) the existence of
unidentified heterogeneous populations of σ2-like receptors, with similar binding properties, that
cannot be discriminated with existing techniques, and 3) an assay artifact due to an
approximately 3.5-fold higher receptor concentration employed in liver membrane assays versus
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brain membrane assays. It should also be noted that because the σ2 receptor has not been purified
to homogeneity, it has not been established that σ2 receptors present in the brain are the same
protein as σ2 receptors found in the liver.
A few points are worth noting regarding the apparent difference in binding affinity for σ2
receptors from liver P2 versus brain P2 membranes. Published studies show that σ2 receptors
reside in lipid rafts [33, 34], and differences in binding of [3H]DTG (with σ1 blocking) have
been observed in partially solubilized rafts isolated from the rat liver P2 fraction using different
detergents (Kd = ~23 nM in 20 mM CHAPS versus Kd = ~170 nM in 1% Triton X-100) but fully
solubilized preparations in these same detergents showed equivalent binding affinities [33, 34].
This suggests that the binding affinity of σ2 can be influenced by manipulating the composition
of lipids and/or proteins that associate with it. Thus, the different complement of lipids found in
the brain versus the liver may result in a σ2 receptor with slightly lower binding affinity. This
observation contrasts with the behavior of the σ1 receptor which appears to maintain consistent
binding affinity for ligands in different sub-cellular fractions, soluble extracts, in purified form,
and in lipid reconstituted purified forms [27, 28, 57, 60]. With regard to the effect of a ~3.5-fold
higher concentration of σ2 receptors in samples prepared with liver membranes (0.04 mg x 9000
fmol/mg in 0.25 ml = 1440 fmol/ml) versus those made with brain membranes (0.4 mg x 500
fmol/mg in 0.5 ml = 400 fmol/ml), a higher receptor concentration alone would be expected to
underestimate ligand affinity [61], where in this case an increased affinity was observed. The
observed differences in binding affinities could still be the result of factors unassociated with
receptor specific binding but the data from liver samples processed with both Brandel and 96well filtration (which gave nearly identical results) suggests this is not due to the filtration format
per se.

As mentioned previously several factors contributed to our choice to use rat liver for all sigma
receptor binding assays performed using the 96-well method. In addition to the historically
demonstrated equivalence of brain and liver for σ1 binding [28-30], and the almost universal use
of rat liver for σ2 determinations, the use of liver membranes has additional advantages,
including: 1) the small amount of membrane required to generate adequate signal reduces the
likelihood for clogging of filters, 2) the use of one tissue for determination of both sigma
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receptor subtypes allows a comparison of σ1 versus σ2 binding in a similar molecular
environment where use of different tissues for determinations introduces some ambiguity in this
measurement, and 3) one batch of liver membrane is adequate for assaying thousands of data
points instead of hundreds per batch (~50-100 g tissue/batch) for typical membrane preparation
scales of rat or guinea-pig brains, facilitating added inter-assay consistency.

Many well characterized membrane bound receptors have been cloned and overexpressed in
cultured cells for use in binding and functional assays. While the use of cultured cells as a source
of membranes for sigma receptor binding has been reported their use is not widespread [62, 63].
Lee et al. [63] cloned human σ1 into MCF7 cells and produced a cell line with Bmax σ1 = 109 ±
24 pmol/mg. Membranes from this cell line were used to analyze a series of 32 compounds,
including several of the reference compounds tested in this study. The Ki values determined for
(+)-pentazocine, haloperidol, BD1063, and (+)-SKF10,047, and fluvoxamine in their study [63]
were similar to the values obtained in this study, suggesting that their system is valid for
assessing σ1 binding. A similar strategy for σ2 is not possible at this time because this protein
has not been cloned. However, Schepmann et al. [62] recently reported the use of human RT-4
cells in binding studies; RT-4 cells contain a moderate expression level of σ2 receptors, (Bmax σ2
= ~2.1 pmol/mg, Bmax σ1 = ~280 fmol/mg). This cell line showed good agreement with binding
in rat liver P2 membranes for the four reference compounds tested [62] and the cell line is
commercially available. While these approaches may be valid, until they are tested more
rigorously or adopted more widely it is difficult to justify making a switch from the more
established tissue sources of sigma receptors.

The results obtained for the 2(3H)-benzothiazolone series examined in this study suggest the 96well filtration method is suitable for application to novel classes of sigma ligands for use in
structure-binding affinity studies. A more thorough discussion of the implications of the results
obtained for this series will be detailed by our collaborators at the University of Mississippi in a
future publication. However, some preliminary conclusions may be drawn including: 1)
increased chain length for the heterocycle linker arm results in loss of selectivity for the σ1
subtype, reflecting marginal changes in Ki at σ1 and significant changes in Ki for σ2, 2) RB74
was identified as a new σ1-selective compound with a 3-fold higher selectivity for σ1 versus σ2
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compared to the lead compound, SN56; RB74 had a Ki σ2/Ki σ1 ratio of ~500 in rat liver P2, and
3) several analogues were identified which retained low nanomolar affinity for σ1 and exhibited
a more than 50-fold preference for σ1 versus σ2. Further, because dramatic differences in
subtype binding were observed in this synthetic series, this study provides useful data for the
continued development of pharmacophore models for both sigma receptor subtypes. It should be
noted that the results of this study are consistent with previous reports of compounds with similar
structures where a longer linker arm results in increased affinity at σ2 [39, 40].

Lipophilicity as measured by octanol/water partition coefficients (logD) has been shown to affect
ligand binding [64-66]. Berardi et al. [66] reported correlations between logD and σ2 binding
affinities for a series of piperazine and piperidine sigma ligands, where an increase in logD for
the piperazine compounds resulted in increased affinity, while increased logD for the piperidine
compounds resulted in a decrease in affinity. To examine the effect of lipophilicity on the
binding of the 2(3H)-benzothiazolone compounds, logD was calculated and compared to binding
affinities determined in this study. No correlation between logD and Ki σ2 was noted for the data
set considered as a whole. When homologous compounds with similar linker chain lengths were
examined, a significant change in logD resulted in a concomitant significant change in the Ki for
σ2 only for linker length n=2 and n=3 when the R group was changed from –H to –(CH3)2CH3.
Therefore, it does not appear that lipophilicity plays a major role in determining the binding
affinity for the 2(3H)-benzothiazolone compounds examined in this study.

In light of the results obtained in this study caution should be exercised with respect to
comparisons of σ2 binding data generated from different organ tissues. Researchers often report
Ki σ2/Ki σ1 selectivity ratios, which due to potential tissue specific differences in binding at σ2
may be misleading when comparing compounds reported by different groups. In contrast,
binding at σ1 appears to remain relatively consistent between rat or guinea-pig brain P2 and rat
liver P2.

The 96-well filtration method presented here has several advantages compared to the
conventional Brandel filtration based method. In addition to greatly reduced radioactive liquid,
solid, vial and scintillation waste the 96-well method also eliminates several labor intensive steps
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and uses less radioligand compared to the Brandel method. Furthermore, because the 96-well
method uses 1/10 the amount of membrane per sample, a single membrane preparation can be
used to process much larger numbers of samples, which reduces inter-run variability and time
spent preparing membranes. Over the course of this study we also observed approximately ½ the
number of “failed” runs versus the conventional filter method where a high non-specific binding
signal compromised precise measurements with Brandel filtration. An additional advantage is
that 96-well plates can be read 2 h after the addition of scintillation cocktail versus 10 h for
filters from the Brandel; this means 96-well filterplate samples can be run the same day as they
are processed whereas Brandel samples typically are run the day after processing.

In conclusion, we have demonstrated the suitability of a 96-well method for the analysis of sigma
receptor binding. This method was validated by assaying reference compounds with the
traditional Brandel cell harvester with rat brain P2 membranes and compared to results obtained
with the 96-well filtration method using rat liver P2 membranes. Excellent correlations were
observed between the two methods for the determination of binding to both σ1 and σ2 subtypes
despite the use of different assay formats and tissue source for sigma receptors. The excellent
correlation for binding of reference compounds at σ1 in rat liver P2 versus rat brain P2 suggests
affinities determined with the new method can be compared to historically reported results
determined in rat or guinea-pig brain membranes. Additionally, because the method employs the
same tissue source as is commonly used for σ2 affinity determinations, the results for σ2 binding
obtained with this method can be compared directly to most reported results for this subtype. The
validity of the method was further demonstrated by a successful structure-binding affinity
analysis of a novel series of 2(3H)-benzothiazolone sigma receptor ligands.
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Table 1. Binding of [3H](+)-pentazocine in rat brain P2 membranes processed by 96-well
filtration.

Rat brain
membrane
(µg)

Non-specific
binding (CPM)

Total binding,
(CPM)

0

194 ± 9

208 ± 8

93

25

876 ± 44

952 ± 131

92

50

785 ± 127

1029 ± 123

76

100

784 ± 63

1325 ± 55

59

62

% Nonspecific binding

[3H](+)-Pentazocine bound, CPM

3000

Total
NSB

2000

1000

0
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50

60

70

Rat liver P2, g

Figure 1. Binding linearity for σ1 receptors in rat liver P2 membranes labeled with 5 nM
[3H](+)-pentazocine. Non-specific binding (NSB) was determined by the addition of 10 µM
haloperidol. Data points represent the mean ± SEM of three determinations at each protein
concentration. The data point at 60 µg total protein corresponds to the point at which the data
deviates from linearity.
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Figure 2. Binding linearity for σ2 receptors in rat liver P2 membranes labeled with 5 nM
[3H]DTG with 300 nM (+)-pentazocine. Non-specific binding (NSB) was determined by the
addition of 10 µM haloperidol. Data points represent the mean ± SEM of three determinations at
each protein concentration. The data point at 60 µg total protein corresponds to the point at
which the data deviates from linearity.
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Table 2. Binding affinities of reference ligands at σ1 receptors.

Ki at σ1 (nM)
Compound

Experimental
Literature
a

Brain/Brandel

Liver/96-well

8.65 ± 0.4

13.3 ± 1.8

57.2 ± 1.9

47.6 ± 3.8

(+)-pentazocine

6.7 ± 1.2

(-)-pentazocine

44.0 ± 1.2

(+)-SKF10,047

28.7 ± 2.8a

287 ± 36

288 ± 24

DTG

74.3 ± 13.9a

57.4 ± 3.3

55.9 ± 3.9

haloperidol

1.9 ± 0.3

3.9 ± 0.5

3.3 ± 0.6

NE100

1.54 ± 0.26b

2.8 ± 0.5

2.0 ± 0.5

BD1063

9.15 ± 1.28c

15.0 ± 2.1

33.4 ± 4.1

AC927

30 ± 2d

61.2 ± 5.6

74.3 ± 2.1

fluvoxamine

36e

64.0 ± 5.2

74.3 ± 9.4

progesterone

338 ± 8f

234 ± 4.4

99.7 ± 3.1

dextromethorphan

652 ± 33g

403 ± 22

214 ± 15

rimcazole

867 ± 185g

2565 ± 36

594 ± 61

SN56

0.56

1.7 ± 0.1

1.6 ± 0.1

a

a

h

NR = not reported.
a

Bowen, 1993. Rat brain P2 with 5 nM [3H](+)-pentazocine for σ1 and 3 nM [3H]DTG with 1 µM dextrallorphan for σ2.

b

Chaki, 1994. Guinea-pig brain. Note: reported value is IC50.

Matsumoto, 1995. Guinea-pig brain P2 with 3 nM [3H](+)-pentazocine for σ1. Rat liver P2 with 3 nM [3H]DTG with 1 µM dextrallorphan

c

for σ2.
d

Matsumoto, 2008. Rat brain P2 with 3 nM [3H](+)-pentazocine for σ1 and 3 nM [3H]DTG with 300 nM (+)-pentazocine for σ2.

Narita, 1996. Rat brain P1/P2 with 5 nM [3H](+)-pentazocine for σ1 and 5 nM [3H]DTG with 1 µM (+)-pentazocine for σ2.

e
f

Hanner, 1996. Guinea-pig brain P3 with 0.3-0.5 nM [3H](+)-pentazocine.

g

Klouz, 2002. Rat brain P2/P3, described as “synaptosomal” with 2-3 nM [3H](+)-pentazocine.

h

Yous, 2005. Guinea-pig brain P2 with 3 nM [3H](+)-pentazocine for σ1 and 3 nM [3H]DTG with 100 nM (+)-normetazocine for σ2.
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Table 3. Binding affinities of reference ligands at σ2 receptors.

Ki at σ2 (nM)
Compound

Experimental
Literature
a

Brain/Brandel

Liver/96-well

1414 ± 207

1067 ± 94

108 ± 4.4

58.1 ± 4.0

(+)-pentazocine

1361 ± 134

(-)-pentazocine

108 ± 6

(+)-SKF10,047

33,654 ± 9,409a

ND

>10,000

DTG

61.2 ± 13.4a

43.3 ± 0.6

24.0 ± 2.3

haloperidol

79.8 ± 20.6

155 ± 2

57.2 ± 2.4

NE100

84.6 ± 32.9b

95.5 ± 1.0

36.2 ± 1.1

BD1063

449 ± 11c

928 ± 40

462 ± 10.4

AC927

138 ± 18d

384 ± 34

94.3 ± 3.1

fluvoxamine

8439e

4818 ± 204

2254 ± 206

progesterone

NR

>10,000

>10,000

dextromethorphan

NR

>10,000

>10,000

rimcazole

NR

1568 ± 154

719 ± 72

SN56

>1000

627 ± 115

248 ± 15

a

a

h

NR = not reported.
a

Bowen, 1993. Rat brain P2 with 5 nM [3H](+)-pentazocine for σ1 and 3 nM [3H]DTG with 1 µM dextrallorphan for σ2.

b

Chaki, 1994. Guinea-pig brain. Note: reported value is IC50.

Matsumoto, 1995. Guinea-pig brain P2 with 3 nM [3H](+)-pentazocine for σ1. Rat liver P2 with 3 nM [3H]DTG with 1 µM dextrallorphan

c

for σ2.
d

Matsumoto, 2008. Rat brain P2 with 3 nM [3H](+)-pentazocine for σ1 and 3 nM [3H]DTG with 300 nM (+)-pentazocine for σ2.

Narita, 1996. Rat brain P1/P2 with 5 nM [ 3H](+)-pentazocine for σ1 and 5 nM [3H]DTG with 1 µM (+)-pentazocine for σ2.

e
f

Hanner, 1996. Guinea-pig brain P3 with 0.3-0.5 nM [3H](+)-pentazocine.

g

Klouz, 2002. Rat brain P2/P3, described as “synaptosomal” with 2-3 nM [3H](+)-pentazocine.

h

Yous, 2005. Guinea-pig brain P2 with 3 nM [3H](+)-pentazocine for σ1 and 3 nM [3H]DTG with 100 nM (+)-normetazocine for σ2.
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Figure 3. Correlation plots for binding of sigma reference ligands to σ1 receptors in (A) rat liver P2
versus rat brain P2 membranes, and (B) rat brain P2 versus literature values determined in rat or guineapig brain membranes. Plots show least squares regression line. Correlation plots yielded Pearson r values
= 0.97 and 0.95 for plot A and B, respectively. [1, SN56; 2, NE100; 3, haloperidol; 4, (+)-pentazocine; 5,
BD1063; 6, (-)-pentazocine; 7, DTG; 8, AC927; 9, fluvoxamine; 10, progesterone; 11, (+)-SKF10,047;
12, dextromethorphan; 13, rimcazole].
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Figure 4. Correlation plots for binding of sigma reference ligands to σ2 receptors in (A) rat liver P2
versus rat brain P2 membranes, (B) rat brain P2 versus literature values determined in rat or guinea-pig
brain membranes. Plots show least squares regression line. Correlation plots yielded Pearson r values =
0.98, and 0.95 for plot A and B respectively. [1, DTG; 2, NE100; 3, (-)-pentazocine; 4, haloperidol; 5,
AC927; 6, SN56; 7, BD1063; 8, (+)-pentazocine; 9, rimcazole 10, fluvoxamine].
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Table 4. Binding affinities for 2(3H)-benzothiazolone compounds for sigma receptors in rat liver
P2 membranes. Linker length (n) and ring size (m) refer to the structure shown in Figure 5.

Linker
length, n

Ring size, m

RB65

1

RB67

Compound

R

Ki (nM)

Ki σ2/Ki σ1

σ1

σ2

0

578 ± 41

8264 ± 500

14

1

3

9.7 ± 0.6

716 ± 30

74

2

2

4.1 ± 0.3

177 ± 26

43

RB4

3

2

3.2 ± 0.02

101 ± 14

31

RB6

4

2

7.0 ± 0.3

2.5 ± 0.3

0.4

RB8

5

2

7.5 ± 0.6

2.4 ± 0.4

0.3

SN56

1

2

1.6 ± 0.1

270 ± 4.7

168

RB10

2

2

1.4 ± 0.1

17.2 ± 1.0

13

3

2

6.1 ± 1.2

4.3 ± 0.3

0.7

RB16

4

2

4.6 ± 0.4

1.6 ± 0.1

0.3

RB18

5

2

6.3 ± 0.9

2.3 ± 0.2

0.4

RB20

2

2

2.2 ± 0.4

15.3 ± 0.9

7

3

2

1.9 ± 0.2

4.4 ± 0.3

2.4

RB24

5

2

12.0 ± 0.7

4.1 ± 0.6

0.3

RB75

1

0

116 ± 15

4787 ± 101

41

RB74

1

2

4.5 ± 0.2

2181 ± 127

483

2

2

3.7 ± 0.3

305 ± 7.0

83

3

2

10.3 ± 0.9

30.3 ± 2.0

3.0

RB30

4

2

12.2 ± 1.1

8.3 ± 0.8

0.7

RB32

5

2

10.4 ± 0.1

1.1 ± 0.1

0.1

RB36

2

2

2.6 ± 0.4

104 ± 1.9

39

3

2

4.8 ± 0.1

21.6 ± 4.2

5

4

2

16.3 ± 0.6

5.7 ± 0.5

0.4

5

2

10.8 ± 0.4

2.3 ± 0.3

0.2

RB2

RB14

RB34

RB26
RB28

RB38
RB40
RB70

-H

-(CH2)2CH3

-(CH2)3CH3

-COCH2CH3

-CO(CH2)2CH3
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N
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Figure 5. Structure of 2(3H)-benzothiazolone analogs. R = H, (CH2)2CH3, (CH2)3CH3, COCH2CH3,
or CO(CH2)2CH3.
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Table 5. Lipophilicity expressed as logD calculated at pH 8 for 2(3H)-benzothiazolone
compounds.

Linker length,
n

Ring size, m

RB65

1

0

8264

0.93

RB67

1

3

716

2.92

2

2

177

1.52

RB4

3

2

101

1.47

RB6

4

2

2.5

1.63

RB8

5

2

2.4

1.92

SN56

1

2

270

3.34

RB10

2

2

17.2

2.82

3

2

4.3

2.6

RB16

4

2

1.6

2.64

RB18

5

2

2.3

2.96

RB20

2

2

15.3

3.14

3

2

4.4

2.94

RB24

5

2

4.1

3.43

RB75

1

0

4787

1.36

RB74

1

2

2181

2.8

2

2

305

2.23

3

2

30.3

2.16

RB30

4

2

8.3

1.7

RB32

5

2

1.1

2.37

RB36

2

2

104

2.72

3

2

21.6

2.25

4

2

5.7

2.47

5

2

2.3

2.67

Compound

RB2

RB14

RB34

RB26
RB28

RB38
RB40
RB70

R

-H

-(CH2)2CH3

-(CH2)3CH3

-COCH2CH3

-CO(CH2)2CH3
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Figure 6. Binding affinity at σ2 receptor (Ki σ2) versus lipophilicity (logD) calculated at pH=8
for homologous 2(3H)-benzothiazolone compounds. The n in the legend denotes the linker chain
length. (A) A; R= -H, B; R= -CH2CH3, C; R= -(CH2)2CH3. (B) D; R= -OCH2CH3, E; R= O(CH2)2CH3.
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CHAPTER 4
A scintillation proximity assay (SPA) for radioligand
binding analysis of sigma receptor ligands
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4.1 Abstract
Sigma ligands exhibit activity in numerous in vivo and in vitro model systems. In vivo, sigma
antagonists can mitigate the toxic and behavioral effects of psychostimulants, while agonists
show efficacy in rodent models of depression. Accordingly, sigma receptors represent a
promising target for therapeutic development. Because there are no established in vitro
functional assays available for routine screening of sigma ligands binding assays are of increased
importance. The conventional cell harvester based filtration method used for radioligand binding
studies with sigma receptors is a low throughput method. 96-well filtration has been
demonstrated to be an improvement over conventional filtration but the scintillation proximity
assay (SPA) offers the potential to further increase throughput and improve accuracy and
precision due to its homogenous nature. In the present work, preliminary data was generated with
SPA, using conventional sigma radioligands in conjunction with rat liver P2 membranes. The
studies show that SPA PVT WGA (polyvinyltoluene, wheat germ agglutinin) beads can be used
for the analysis of ligand binding at both σ1 and σ2 receptors. Competition assays with a limited
number of reference ligands showed good agreement with results obtained using 96-well
filtration for both receptor subtypes. Non-specific binding for σ1 receptors labeled with [3H](+)pentazocine was approximately 40%. Assays for σ2 receptors had an effective non-specific
binding signal of 60% due in part to the necessity of blocking σ1 binding, which accounts for
approximately one half of the total specific binding of [3H]DTG. The results demonstrate that
SPA technologies represent a feasible alternative to currently used filtration based methods for
the determination of sigma ligand binding affinities. However, additional studies will be
necessary to formally validate this method, and a subtype specific radioligand for σ2 receptors
may be required to reliably assess σ2 binding using SPA.
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4.2 Introduction
Radioligand binding continues to serve as a primary screen for new sigma receptor ligands
because there are no medium or high throughput in vitro assays for sigma receptor activity. The
scintillation proximity assay (SPA) is a relatively new technology that is designed for use in
enzymatic and radioligand binding assays. SPA utilizes microscopic beads that produce photons
when radiolabeled molecules are in close proximity to the bead surface. SPA beads for
radioligand binding assays exploit the interaction of glycosylation sites on cell membranes and
bead bound wheat germ agglutinin (WGA), or charge interactions between cell membranes and
bead bound polylysine, that localize membrane-bound receptors close to the bead surface [1-3].
The subsequent binding of radioligands to the bead associated membrane-bound receptors gives
rise to a signal commensurate with the amount of bound radioligand [1-3].

Conventional filtration-based binding assays are tedious, time consuming, and generate a
significant amount of radioactive waste. In SPA all the assay components are combined and read
in a single assay plate, resulting in less than 25 ml of mixed radioactive waste per 96 samples,
compared to the ~1 l of aqueous radioactive waste and 300-500 ml of mixed scintillation fluidradioactive waste that are generated during processing of 96 samples using a conventional
Brandel cell harvester. In addition to reductions in waste, the reduced number of manipulations
and the elimination of the filtration step in SPA results in increased accuracy and precision
relative to filtration assays [1-4]. Additionally, because SPA can also be performed in 384 and
1536 well plates the method is amenable to use in high throughput screening (HTS) [1, 4-6].

SPA assays have been reported for a number of classical membrane bound receptors including
serotonin, acetylcholine, and opioid receptor subtypes [7-9]; application of the SPA technology
to the analysis of sigma receptor binding has not been reported. Four of the five SPA bead types
designed for radioligand binding experiments rely on capture of membranes via interactions of
wheat germ agglutinin (WGA) on the bead surface and N-acetyl-β-D-glucosaminyl residues of
glycoproteins [1-3]. Because sigma receptors normally reside subcellularly [10] and the P2
fraction that is typically used for sigma receptor binding experiments consists largely of
mitochondria and the mitochondrial associated membrane (MAM) [11, 12] it was not known if

83

WGA binding competent moieties were present in this membrane preparation. Therefore, the
poly-l-lysine bead type was also assessed in these studies. In total five different bead types are
available for use in radioligand binding studies: PVT WGA, PVT-PEI Type A, PVT-PEI Type
B, Ysi WGA and Ysi poly-l-lysine. PVT designates that the bead base is composed of
polyvinyltoluene, while Ysi indicates a base material composed of yitrium silicate. WGA
designates an untreated bead with a coating of wheat germ agglutinin, while PEI indicates that
the bead was treated with polyethyleneimine either before (Type A) of after (Type B) coating
with WGA.

Implementation of this technology using tritiated radioligands requires receptor expression levels
greater than or equal to 2 pmol/mg in order to generate adequate signal for accurate
measurements [1-3, 13]. The P2 fraction of rat liver obtained through differential centrifugation
contains levels of σ1 and σ2 receptors that exceed this requirement [14] and was thus chosen as a
source of membrane.

To investigate the feasibility of using SPA for competition binding studies of sigma receptor
ligands, experiments were performed with the established σ1 receptor radioligand, [3H](+)pentazocine [15] in conjunction with rat liver P2 membranes and each of the five available SPA
bead types. Preliminary studies were performed to determine basic assay parameters including:
1) optimum SPA bead type, 2) incubation time, and 3) membrane to bead ratio. Following
determination of working conditions the assay was applied to the competition binding analysis of
three reference sigma ligands. A more limited assessment of binding at σ2 receptors was carried
out using [3H]DTG with the assay conditions determined with [3H](+)-pentazocine.

4.3 Materials and Methods

4.3.1 Reagents and chemicals
[3H](+)-Pentazocine (specific activity = 29 Ci/mmol) and [3H]DTG (specific activity = 53.3
Ci/mmol) were purchased from Perkin Elmer (Boston, MA). (+)-Pentazocine, haloperidol, 1,3di-o-tolylguanidine

(DTG),

sucrose,

NaCl,

dimethylsulfoxide

(DMSO)

and

tris(hydroxymethyl)aminomethane (Tris), were purchased from Sigma-Aldrich (St. Louis, MO).
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NE100

(4-methoxy-3-(2-phenylethoxy)-N,N-dipropylbenzeneethanamine

hydrochloride),

BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine dihydrochloride), and fluvoxamine
maleate

were

from

Tocris

Bioscience

(Ellisville,

MO).

fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)–one)

SN79
was

(6-acetyl-3-(4-(4-(4-

obtained

from

Dr.

Christopher McCurdy from the University of Mississippi (University, MS). Coomassie Protein
Assay reagent was purchased from Fisher Scientific (Pittsburgh, PA). Scintillation proximity
assay (SPA) beads were from GE LifeSciences (Piscataway, NJ).

4.3.2 Radioligand solutions
Solutions of [3H](+)-pentazocine and [3H]DTG were prepared in 50 mM Tris, pH 8.
Concentrations of radioligand solutions were calculated based on CPM measurements and
specific activities as reported by the manufacturer.

4.3.3 Rat liver P2 membrane preparation
Rat liver P2 homogenates were prepared as described previously and outlined below from frozen
tissues obtained from Pel-Freeze (Matsumoto et al., 1995). Tissues were homogenized batchwise with a Potter-Elvehjem homogenizer (5-10 strokes with motor driven Teflon pestle) in icecold 10 mM Tris-sucrose buffer (0.32 M sucrose in 10 mM Tris, pH 7.4) using 10 ml buffer per
g of tissue with ~3 g of tissue per batch. Homogenates from multiple batches were combined and
centrifuged for 10 min at 1,000 x g, at 4 °C. Supernatants were decanted, combined and
centrifuged for 15 min at 31,000 x g, at 4 °C. To reduce levels of bound endogenous ligand(s)
the resulting P2 membrane was washed as follows: 1) pellets were re-suspended in 10 mM Tris,
pH 7.4 using 3 ml buffer per g of wet tissue, 2) the resulting suspension was incubated for 30
min at 25 °C, 3) following incubation, the suspension was centrifuged for 15 min at 31,000 x g,
at 4 °C. The resulting pellets were re-suspended in 10 mM Tris, pH 7.4 buffer at a final
concentration of 1 g starting tissue weight/1.5 ml. Tissue preparations were aliquoted in 1 ml
portions and stored at -80 °C. The Bradford assay was used to quantitate protein concentration
(Bradford, 1976).
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4.3.4 General SPA assay considerations
Assays utilized 50 mM Tris, pH 8 buffer which is the buffer most often cited in the literature for
the analysis of sigma receptor binding [16]. Assay volumes were 0.2-0.3 ml, depending on the
experiment. PVT WGA beads gave the best results and were used for most experiments except
where noted. Non-specific binding was determined with 10 µM haloperidol. Unless otherwise
noted membranes and radioligand (and test ligand or haloperidol) were incubated for two hours
at room temperature (RT) prior to the addition of SPA beads; samples were subsequently
incubated at RT for various time periods prior to taking scintillation readings. Incubations were
performed without agitation. Typically, single point determinations were made for samples,
except for total and non-specific binding controls which were prepared in duplicate, or where
additional replicate samples were prepared as indicated below. All samples were prepared in 0.5
ml polypropylene tubes and read with the tubes placed in 6 ml scintillation vials on a Beckman
LS6500 scintillation counter (Brea, CA).

4.3.5 Determination of optimum bead type
Initial experiments were conducted to determine the bead type with the best performance. For
each of the five bead types available for radioligand binding, samples were prepared as follows:
50 µl of 60 nM [3H](+)-pentazocine was added to 30 µg of rat liver P2 membrane in 150 µl
buffer. Samples were vortexed and incubated for 2 h at RT. Following incubation, a 100 µl
aliquot of bead solution containing 2 mg beads in buffer was added to samples which were then
vortexed and incubated at RT. Samples were read on the scintillation counter at 2 h and 20 h
following addition of the SPA beads. For determination of the contribution of “proximity
effects” to the non-specific binding signal an additional set of samples was prepared that were
identical to samples prepared for total binding measurements, except membrane was omitted.
Proximity effects describe signal due to radioligand that is in close enough proximity to excite
the beads but is not bound to membrane or receptor.

4.3.6 Determination of binding capacity of PVT WGA beads for rat liver P2 membranes
To determine the optimum amount of rat liver P2 membrane to use with 1 mg of PVT WGA
beads, samples were prepared as follows: 50 µl of 40 nM [3H](+)-pentazocine was added to
samples containing from 0 to 20 µg (in 2 µg increments) rat liver P2 membrane in 50 µl buffer.
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Samples were vortexed and incubated for 2 h at RT. Following incubation, a 100 µL aliquot of
bead solution containing 2 mg beads in buffer was added to samples which were then vortexed
and incubated at RT. Samples were read at ~10, 15 and 20 h following addition of beads.
4.3.7 Determination of σ2 binding with [3H]DTG
To determine if SPA could be used for the analysis of σ2 binding, samples were prepared with
the same procedures that were used for σ1 except [3H]DTG was used for receptor labeling and
binding of [3H]DTG to σ1 was blocked by the addition of (+)-pentazocine. Samples were
prepared with 16 µg rat liver P2 membrane with 10 nM [3H]DTG, 1 µM (+)-pentazocine and 2
mg of PVT WGA beads in a final volume of 200 µl of 50 mM Tris, pH 8. Radioligand and
membrane were pre-incubated for 2 h in 100 µl of 50 mM Tris, pH 8 prior to addition of 2 mg
SPA beads in 100 µl of 50 mM Tris, pH 8. Samples were read at 1, 7 and 20 h following addition
of SPA beads.

4.3.8 Competition binding assays
To test the suitability of the SPA method for use in determining sigma receptor binding affinities,
DTG, haloperidol, (+)-pentazocine and SN79 were used as reference compounds and were
assayed using optimized conditions determined from preliminary studies. Stock solutions of test
ligands were prepared in DMSO or deionized water at 5 or 25 mM. Dilutions of reference
ligands for competition studies were made with assay buffer (50 mM Tris, pH 8). Samples were
prepared as described previously containing 1 mg of PVT-WGA beads, 8 µg rat liver P2, and 10
nM [3H](+)-pentazocine for σ1 assays, or 10 nM [3H]DTG for σ2 assays, in a final volume of
200 µl. Samples were pre-incubated for 2 h in 100 µl of 50 mM Tris, pH 8 prior to addition of 1
mg SPA beads in 100 µl of 50 mM Tris, pH 8. Samples were read 20 h following addition of
SPA beads. Test compounds were assayed at 11 concentrations varying from 0.001 – 10 µM.

4.3.9 Data analysis
The competition binding data were analyzed with GraphPad Prism software (San Diego, CA)
using a one-site nonlinear regression model to determine the concentration of ligand that inhibits
50% of the specific binding of the radioligand (IC50 value). Ki values were calculated from the
IC50 using the Cheng-Prusoff equation [17].
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4.4 Results

4.4.1 Determination of optimum bead type
As shown in Figure 1, of the five bead types available, PVT PEI Type A and PVT WGA beads
gave the highest total binding with the lowest non-specific binding (NSB) with [3H](+)pentazocine. Samples were read at 2 and 20 h; specific binding did not change for PVT-PEI
Type A or Ysi WGA over this time period while specific binding for PVT-PEI Type B, PVT
WGA and Ysi poly-l-lysine increased 20-30%. At 20 h post bead addition, non-specific binding
(NSB), as defined by the addition of 10 µM haloperidol, was 40%, 55%, 46%, 42%, and 44%
respectively for PVT-PEI type A, PVT-PEI type B, PVT WGA, Ysi WGA and Ysi poly-l-lysine
beads. Signal due to proximity effects, i.e., the amount of signal observed in the absence of
membrane versus in its presence, with 10 µM haloperidol added to both samples, ranged from
35% to 50% and was 44% for the PVT WGA beads.

4.4.2 Determination of optimum incubation time
Over the course of these studies samples were read at various timepoints following the addition
of SPA beads to samples. For σ1 binding determinations with [3H](+)-pentazocine the highest
level of specific binding occurred around 20 h with no change in signal with incubation up to 25
h. Interestingly, determinations of σ2 binding with [3H]DTG had the highest specific binding
signal at 1 h, compared to identical samples incubated for 7 or 20 h. Additional time points were
not examined with [3H]DTG.

4.4.3 Determination of binding capacity of PVT WGA beads for rat liver P2
The binding capacity of the PVT WGA bead was determined by adding varying amounts of
membrane, labeled with [3H](+)-pentazocine, to 1 mg of bead per sample. Figure 2 shows the
binding function is curvilinear from 0 to 20 µg membrane with a linear increase in non-specific
binding over this range resulting in a linear region of specific binding from 0-10 µg of added
tissue per mg of bead in 200 µl of 50 mM Tris, pH 8. In addition to varying receptor
concentration with a fixed bead amount, we also tested the effect of bead amount with a fixed
quantity of membrane. With 30 µg of membrane combined with 0.25 to 3 mg of SPA beads the
specific binding increased linearly but non-specific binding remained constant at approximately
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35%. Therefore, it does not appear that excess membrane adversely affects background but as
demonstrated previously it does lead to non-linear binding of radioligand. It also does not appear
that there is any advantage to using more than 1 mg/well of SPA beads with our current
procedure.
4.4.4 Determination of σ2 binding with [3H]DTG
To determine if SPA could be used for the analysis of σ2 binding, samples were prepared with
the same procedures that were used for σ1 binding except [3H]DTG was used for labeling sigma
receptors. Because [3H]DTG does not discriminate between σ1 and σ2 receptors, exhibiting
nearly equal affinity for both subtypes [15], the standard method of blocking σ1 with (+)pentazocine was required [15]. Samples prepared with 16 µg rat liver P2 membrane with 20 nM
[3H]DTG and 2 mg of PVT WGA beads resulted in non-specific binding of ~42%. This is
similar to the level observed with [3H](+)-pentazocine. Addition of (+)-pentazocine to block σ1
results in a signal approximately 50% lower than in its absence. This produced an effective 40%
specific binding at σ2. These data are shown graphically in Figure 3. Signal due to proximity
effects for [3H]DTG was approximately 50% compared to approximately 45% observed with
[3H](+)-pentazocine analyzed under similar conditions.

4.4.5 Competition binding of established sigma ligands
Competition binding curves for haloperidol, (+)-pentazocine and DTG binding to σ1 receptors
were generated with samples containing varying concentrations of the test ligands, 10 nM
[3H](+)-pentazocine, 8 µg membrane and 1 mg PVT WGA beads in 200 µl total volume. The
binding curves are shown in Figure 4. For haloperidol and (+)-pentazocine, calculated
equilibrium dissociation constants (Ki) were in excellent agreement with values determined by
96-well filtration binding using rat liver P2. For haloperidol, Ki (SPA) = 3.4 nM versus Ki (96well) = 3.3 ± 0.6, and for (+)-pentazocine, Ki (SPA) = 15.8 nM versus Ki (96-well) = 13.3 ± 1.8.
The “96-well” values in the preceding comparison are from the 96-well filtration study that is the
subject of Chapter 3 of this document. Agreement between SPA and 96-well filtration was fair
with DTG with Ki (SPA) = 228 nM versus Ki (96-well) = 55.9 ± 3.9. A competition binding
curve for SN79 binding to σ2 was generated with samples containing varying concentrations of
SN79, 10 nM [3H]DTG, 1 µM (+)-pentazocine, 8 µg membrane and 1 mg PVT WGA beads in
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200 µl total volume. The resulting binding curve is shown in Figure 5. The calculated
equilibrium dissociation constant was in fair agreement with the value reported in the literature
(determined in our lab) using a conventional filtration assay with rat brain P2. The value
determined in this study was Ki (SPA/rat liver) = 23.8 nM versus Ki (conventional/rat brain) =
7.00 ± 0.09 reported by Kaushal et al [18].

4.5 Discussion

The results of this study suggest that SPA is a feasible alternative technology for determining
competition binding affinities of sigma receptor ligands; the Ki values for reference compounds
determined with SPA in this study were in good agreement with binding affinities determined by
conventional filtration methods. However, additional work will be required to improve the
performance of this method because background levels currently exceed levels recommended by
the NIH for SPA assays [19]. Efforts to reduce background were not made in these preliminary
studies; however, improvements may be achieved through: 1) the use of more highly purified
receptor preparations, 2) the inclusion of buffer additives, and 3) in the case of the analysis of σ2
receptor binding, the use of a subtype specific radioligand.
The conditions used to determine Ki values for binding to σ1 receptors resulted in a non-specific
signal of approximately 40% of the total signal. Approximately 70% of this non-specific signal
can be attributed to membrane binding, with the remainder due to proximity effects. This
conclusion is based on signal observed in the presence of added membrane versus signal
observed in the absence of added membrane. Because most of the non-specific signal is due to
membrane binding this may reflect the quality of the radioligand. [ 3H](+)-Pentazocine and other
radioligands have in our hands been demonstrated to degrade and a primary indicator is
increased non-specific binding. The benchmark would be the level of non-specific binding (1520%) that was observed for rat liver P2 membrane processed by 96-well filtration, as determined
in studies detailed in Chapter 3 of this document.

The high background level we observed may be improved by further purification of the receptor
preparation or the use of different radioligands. The effect of membrane source and radioligand
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has been tested in defined systems and differences in signal due to non-specific sources can be
dramatic. Carrick et al. [8] compared [3H]LSD binding to membranes and whole cells from CHO
and Hela cells expressing human 5-HT6 receptors. They found that membranes from CHO gave
less than 10% specific binding but whole cells yielded >80% specific binding [8]. Similarly,
Hela membranes gave <30% specific binding while whole cells treated with sodium boride gave
70-80% specific binding [8]. They also tested [3H]LSD, [125I]LSD and [3H]5-HT with the CHO
membranes and found <30%, <10% and <20% specific binding respectively [8]. These
experiments show very clearly that the receptor preparation and radioligand can have a
significant impact on background levels.

The results of our studies show that SPA WGA beads gave the optimum signal to noise with a
membrane to bead ratio of 8 µg rat liver P2 per mg of SPA bead. The amount of membrane that
will bind to SPA WGA beads is limited to 10-30 µg membrane/mg of bead [1-3]. Therefore, the
amount of membrane bound per mg of bead we observed was consistent with expectations.
Significant improvements in signal to noise or reductions in the amount of SPA bead used per
well may be realized for σ1 binding assays if a cell line over-expressing σ1 receptors are used as
a source of membranes. Filter binding assays with MCF-7 cells stably expressing human σ1
receptors at ~100 pmol/mg (determined with [3H](+)-pentazocine) yielded similar binding
affinities for reference compounds compared to historical values determined in tissues [20].
Therefore, with this or a similar cell line over-expressing σ1 receptors, there is the potential for
binding 20 to 30-fold more receptors for the same mass of membrane, relative to rat liver P2
membranes that contain σ1 receptors with a Bmax of ~3 pmol/mg. The increased number of bead
bound receptors would be expected to generate higher specific signal levels for a given amount
of SPA bead. Cell lines over-expressing σ2 receptors cannot be produced at this time because the
σ2 receptor has not been cloned; therefore, this strategy cannot be utilized for the analysis of the
σ2 subtype.
Incubation times of approximately 20 hours were required for a stable SPA signal with σ1
receptors. Relatively long incubation times are utilized in most published SPA studies [7, 9].
Rodgers et al. [7] reported binding of [3H]DPN (diprenorphine) to human µ opioid receptors
expressed in CHO cells with WGA SPA and a total incubation time of 8 h. Hui et al. [9] used
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WGA beads with HEK293 cells expressing α4β2 nAChR, labeled with [3H]cytosine and
incubated for 12 h. Our experiments suggest σ1 receptor stability is not a problem because
signals for σ1 binding increased until 20 h and were stable to at least 25 h. It is not clear why the
signal for σ2 receptors was highest at 1 h versus 7 or 10 h. If stability issues emerge as the assay
is further optimized, as evidenced by irreproducible results, or derived Ki values for reference
compounds that are inconsistent with known values, addition of protease inhibitor(s) to assay
samples may be necessary. Addition of protease inhibitors to receptor preparations for
radioligand binding is a common practice [21] and would not be expected to adversely affect the
analysis.
[3H]DTG was successfully utilized to label σ2 receptors in our study. DTG does not discriminate
between σ1 and σ2 receptors, exhibiting similar affinity for both subtypes, with Ki σ1 = ~74 nM
and Ki σ2 = ~61 nM [16]. Consequently, it was unclear whether [3H]DTG would yield adequate
specific signal with SPA to support use in further studies. The results suggest that adequate
signal is obtained with [3H]DTG but because only 40% of total binding was specific relative to
σ2 after blocking σ1 receptors this assay is considerably less than optimal. However, the binding
affinity determined for SN79 was in fair agreement with the value determined by 96-well
filtration despite the high non-specific signal. A significant improvement may be realized with
the development and introduction of a higher affinity and/or more selective σ2 radioligand.

In conclusion, it appears that SPA represents a potentially useful format for assaying sigma
receptor radioligand binding. A major drawback of the method as currently configured is the cost
of SPA beads which are approximately $1 per mg or $1/well. While in the final analysis, this
may be cost competitive with conventional filtration assays if one factors in labor and other
costs; a reduction in the amount of SPA beads required per sample well by a factor of 2 to 4-fold
would make the method significantly more attractive. This may be possible if radioligands with
higher specific activity become available (e.g., [125I]) or if cell lines over-expressing receptors
are used as a source of membranes. However, this method in its current form may still prove
useful in situations where a researcher has access to a scintillation counter, but does not have a
cell harvester. It should be noted that the studies presented here utilized a standard scintillation
counter for reading samples, not a 96-well plate specific counter.
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Figure 1. Binding of [3H](+)-pentazocine to rat liver P2 membranes analyzed with five SPA
bead types. Samples contained 10 nM [3H](+)-pentazocine, 30 µg rat liver P2, and 2 mg SPA
beads, in a total volume of 300 µl of 50 mM Tris, pH 8 buffer. (A) For the determination of nonspecific (NSB) binding identical samples were prepared containing 10 µM haloperidol. (B) For
the determination of background due to the interaction of beads with radioligand (No
membrane), samples were prepared containing only radioligand, 10 µM haloperidol, and beads.
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Figure 2. Binding linearity of [3H](+)-pentazocine to rat liver P2 with PVT WGA SPA beads.
Samples contained 10 nM [3H](+)-pentazocine, varying amounts of rat liver P2, and 1 mg WGA
SPA beads, in a total volume of 200 µl. Data points represent single determinations. (A) Total
and non-specific binding (NSB) for 0-20 µg rat liver P2/mg of SPA beads. (B) Total and nonspecific binding for the linear range of binding.
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Figure 3. Binding of [3H]DTG to rat liver P2 membranes with PVT WGA SPA beads. Samples
contained 10 nM [3H]DTG, 16 µg of rat liver P2, and 2 mg WGA SPA beads, in a total volume
of 200 µl. Data shown is for 1 h time point which resulted in maximum signal versus 7 and 20 h
readings. Binding due to σ2 and NSB (σ1 block) was determined by adding 1 µM (+)pentazocine. Non-specific binding (NSB) was determined by adding 10 µM haloperidol. Data
points represent triplicate determinations; error bars indicate SEM.

95

[3H](+)-Pentazocine bound, CPM

1250

DTG
Haloperidol
(+)-Pentazocine

1000
750
500
250
-13 -12 -11 -10 -9

-8

-7

-6

-5

-4

-3

log [Ligand, M]

Figure 4. Competition binding curves for DTG, haloperidol, and (+)-pentazocine versus [3H](+)pentazocine at σ1. Samples contained 10 nM [3H](+)-pentazocine, 8 µg rat liver P2, and 1 mg
WGA SPA beads, in a total volume of 200 µl. Test ligands were added at 11 concentrations from
1 pM – 100 µM. Data points represent single determinations.

96

[3H]DTG bound, CPM

1500
1250
1000
750
500
-12 -11 -10 -9

-8

-7

-6

-5

-4

-3

log [SN79, M]

Figure 5. Competition binding curve for SN79 at σ2 receptors. Samples contained 10 nM
[3H]DTG, 1 µM (+)-pentazocine, 8 µg rat liver P2, and 1 mg WGA SPA beads, in a total volume
of 200 µl. Test ligands were added at 11 concentrations from 1 pM – 100 µM. Data points
represent single determinations.
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CHAPTER 5
Development of an Alphascreen assay for the
determination of the in vitro functional activity of σ1
ligands
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5.1 Abstract

The σ1 receptor represents an attractive drug development target for a number of therapeutic
indications including cancer, depression, psychostimulant abuse, and stroke. Functionally, σ1
receptors appear to operate primarily via protein–protein interactions and have been shown to
modulate the activity of a variety of ion channels and signaling molecules. Currently there are no
in vitro functional assays available that are amenable to routine use for the determination of σ1
ligand activities. The availability of such an assay would greatly aid in the development of σ1
targeted therapeutics by providing a rational approach to selecting compounds for in vivo
evaluation and in facilitating design of new synthetic σ1 ligands. A recently identified proteinprotein interaction between σ1 and binding immunoglobulin protein (BiP) appears to provide a
relevant target for selectively evaluating the functional activity of σ1 receptor ligands.
Alphascreen was chosen as a platform for development of an assay that exploits the disruption of
this interaction as a read-out of σ1 activation. The current studies utilized Alphascreen for
experiments with purified affinity-tagged σ1 and BiP proteins in a cell free system, and an
ELISA format was utilized to examine the behavior of σ1/BiP in lysates prepared from cultured
cells and animal tissues. The Alphascreen experiments were unsuccessful due in part to the
apparent interaction of σ1-FLAG with the nickel-chelate donor bead that was intended to interact
specifically with 6XHis-BiP. However, the proposed Alphascreen scheme performed as designed
with a control peptide that mimicked the intended interactions of the affinity tags with donor and
acceptor beads, and yielded important information for the design of future schemes. Attempts to
capture σ1-FLAG by conventional immunoprecipitation with a FLAG affinity resin were
unsuccessful, despite successful pulldown of a control bacterial alkaline phosphatase FLAG
fusion protein in this same system. Attempts to capture σ1 from rat liver or CHO cell lysates on
polystyrene ELISA plates passively coated with σ1 or BiP antibodies were also unsuccessful.
Despite predominantly negative results this preliminary assessment provided valuable data for
future studies. This data coupled with a recent report of a simple procedure for isolating
endogenously expressed σ1/BiP complexes suggest a functional assay for σ1 ligands based on
Alphascreen remains a viable research goal. Additional work is proposed that addresses the
shortcomings observed in the current work.
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5.2 Introduction
The σ1 receptor functions as a chaperone protein and modulates the activities of ion channels [110]. This modulatory role can be affected by well-established ligands that operate in an
agonist/antagonist relationship with σ1 receptors [2-4, 7, 11, 12]. Importantly, σ1 receptors are
also known to translocate from the mitochondrial associated membrane (MAM) to the
endoplasmic reticulum (ER) and plasmalemma in response to agonist ligand stimulation,
assuming different roles depending on their cellular location [2, 13, 14]. Currently there are no in
vitro assays available that are amenable to routine use for screening σ1 ligand activities. The
availability of such a method would facilitate more efficient development of σ1 receptor ligands
as potential therapeutics. Therefore, we sought to develop an in vitro assay based on the recently
identified ligand sensitive interaction between σ1 and binding immunoglobulin protein (BiP) [3].
This interaction is disrupted in the presence of K+, Mg2+, ATP and established sigma agonist
compounds, and is promoted in the presence of Mn2+, Ca2+ and sigma antagonists, and thus
appears to provide a relevant target for evaluating the functional activity of σ1 receptor ligands
[3, 15].
In 2007 Hayashi and Su [3] reported that the interaction of σ1 receptors and BiP regulates Ca2+
signaling between the ER and mitochondria via IP3 receptors localized at focal points called the
MAM. The σ1/BiP complex was observed by Western analysis following immunoprecipitation
of σ1 or BiP from CHAPS (3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate)
lysates of wild-type CHO (Chinese hamster ovary) cells, and CHO cells expressing recombinant
σ1-EYFP (enhanced yellow fluorescent protein) [3]. The dose-dependant sigma receptor agonist
sensitive behavior of this σ1/BiP complex was demonstrated by co-immunoprecipitation studies
with crude lysates of cells expressing σ1-EYFP exposed in situ to sigma ligands [3]. Application
of sigma receptor antagonists in this system prevented the action of agonists but had minimal
effect when they were administered alone.

Additional studies with a GST (glutathione S-transferase) fusion construct of the ER luminal
domain of the σ1 receptor (GST-Sig-1R116-223) coupled to sepharose beads provided evidence
that the interaction of σ1 with BiP is through this domain and can occur in a lipid- and cell-free
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environment [3]. Using this system, recombinant BiP was precipitated from a simple buffer
comprised of 50 mM Tris, pH 7.4, 0.5% NP-40, and endogenous BiP was precipitated from
crude lysates of rat tissue homogenates [3]. Further, the interaction of the construct and
recombinant BiP was sensitive to Mn2+ and Ca2+, similar to the behavior of the σ1-EYFP/BiP
complex observed in CHAPS cell lysates from CHO cells expressing σ1-EYFP [3]. Because this
construct does not contain the putative ligand binding site(s) this system would not be expected
to respond to application of sigma ligands but the effect of application of ligands as a control was
not reported. Therefore, it is not certain that the interaction observed in this model is identical to
the sigma ligand sensitive interaction detected in CHO cell lysates. However, the combined
evidence strongly suggests that the observed interaction is the same in CHO cells and this model.
Together, these studies provide support for our proposed approach to utilize lysates from liver or
cultured cells, or recombinant proteins as a source of the σ1/BiP complex for development of a
functional assay based on exogenous application of sigma ligands.
A number of in vitro and ex vivo systems have been reported which respond to σ1 agonists in a
predictable manner [16-19]. However, none of these methods is amenable to high throughput
use. Moreover, these assays rely on measurement of effects downstream of σ1 activation and
thus do not provide the simplicity or relevancy that an assay based on the interaction σ1 and BiP
would. The phenytoin-induced modulation of agonist binding at σ1 in guinea-pig brain
membrane homogenates is an established effect that appears to distinguish σ1 agonists from
antagonists [20-23]. However, this effect cannot be exploited as a quantitative activity assay and
the mechanism of the effect is unknown. Cell-based assays that exploit changes in Ca2+ levels
lack the quantitative precision and dynamic range required to adequately capture accurate doseresponse curves, and also represent downstream effects of receptor activation [16]. Quantitative
cell based assays relying on σ1 agonist induced neurite outgrowth [19, 24] also depend on
downstream effects and have so far only been demonstrated with a limited number of
compounds. The ligand sensitive σ1/BiP interaction represents a mechanism that is: 1) of
relatively low complexity, 2) appears to be the first step in a cascade of σ1 activities as σ1
translocates in response to ligand stimulation or cellular stress [3, 11], and 3) is amenable to
examination with well-established immunological based techniques. Therefore, we believe an
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assay based on the agonist sensitive interaction of σ1 and BiP provides the best approach
currently available for screening the functional activity of σ1 ligands.

Assay formats that could potentially facilitate measurement of the intact versus the disrupted
σ1/BiP complex include conventional immunoprecipitation, ELISA, Alphascreen, and Surface
Plasmon Resonance (SPR). Alphascreen, the proposed assay format for our studies, is
immunologically based, relying on recognition of native epitopes, or recognition of tagged overexpressed proteins [25-28]. Alphascreen beads are available with a variety of common
immunological substrates attached (streptavidin, protein A/G, anti-affinity tag antibodies, etc.),
providing considerable flexibility in designing assays [27, 28]. Method development is fast, and
assays, once developed, are easy to perform with only addition and mixing of components
required prior to reading on a plate reader. Conventional immunoprecipitation and ELISA
formats are useful for determining the appropriate bead scheme and determining assay conditions
but ultimately a properly-designed Alphascreen assay can facilitate medium and high throughput
analysis with considerably less effort than either of these methods. Moreover, Alphascreen is
more sensitive and has a higher dynamic range than ELISA, allowing for more precise
determinations of EC50s [25]. SPR may provide an alternative and perhaps superior means of
quantitating the σ1/BiP interaction; however, at this stage of method development it does not
provide the flexibility to investigate experimental variables as efficiently as is possible with our
proposed methods. Indeed, the requirement of determining the best attachment method,
corresponding SPR chip and instrumental parameters only serves to compound the complexity of
the primary goals of observing an in vitro interaction of σ1/BiP, and the effect of sigma ligands
on this interaction. Therefore, until operational parameters are better defined, SPR does not offer
any obvious advantages over our proposed methods.
To exploit the interaction of σ1 and BiP for the development of an immunologically-based in
vitro assay numerous factors must be considered which include: sample source, antibodies, assay
format, sample preparation, and the assay matrix. Potential sources of σ1 and BiP proteins
include animal tissue or cell culture derived membranes or lysates, where cell culture derived
samples can be from wild-type cells or cells expressing recombinant proteins with affinity tags.
Tagged proteins can also be purified from the over-expressed systems and used in a cell free
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system. Antibodies are available for several native epitopes on both σ1 and BiP. While
antibodies for affinity tags are highly specific and provide strong interactions, these tags may
interfere with the σ1/BiP complex. Further, sample preparation and assay matrices must be
compatible with the chosen assay format and potential involvement of lipids and/or unidentified
protein partners in the functional σ1/BiP complex must also be considered.
Despite evidence that a σ1/BiP-like complex can exist in cell free conditions [3], it is not known
if the σ1 ligand sensitive functional activity of the σ1/BiP complex depends on the complex lipid
environment of the MAM or if unidentified protein partners are involved. A number of studies
have demonstrated that detergent solubilized tissues yield σ1 complexed with unidentified lipids
and/or proteins [29-32]. As a general rule solubilization conditions play a significant role in
determining the composition of

membrane lysates [33]; therefore, specific detergents and

conditions (e.g. temperature and time) utilized to isolate the σ1/BiP complex may determine
whether or not lipids or cofactors that could be necessary for functional activity are co-isolated.

Recent studies by Hayashi and Fujimoto [34] rigorously characterized the lipid components of
MAM and demonstrated that they correspond to the σ1 receptor containing detergent resistant
microdomains (DRMs) obtained following solubilization with Tx-114 [34]. This series of studies
also showed that cholesterol and ceramides serve to anchor σ1 at the MAM, and that solubilized
σ1 preferentially associates with ceramides. Work by Palmer et al. [35] also supports an intimate
relationship between 1 and cholesterol, where cholesterol binding domains in 1 form part of
the putative ligand binding site [35].

With regards to the possibility of the involvement of unidentified protein partners or cochaperones in the σ1/BiP complex, σ1 has been reported to directly associate with a number of
proteins including: K+ channels [5], IP3 type 3 receptors, ankyrin proteins [3, 4], voltage gated Ltype Ca2+ channels [9] and acid-sensing ion channels [36]. In each of these studies coprecipitation provided evidence of a direct protein-protein interaction with σ1 receptors. Hayashi
and Su [3] also reported detecting small amounts of unidentified proteins in their
immunoprecipitations of σ1/BiP from CHO cells but it is not known if these participate in the
σ1/BiP interaction. Therefore, there is the possibility that additional unidentified protein partners
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could be involved in the interaction of σ1 and BiP which would dictate that activity assays focus
on biologically derived proteins as opposed to recombinant proteins.

A very recent study by Ha et al. [15] using RGC-5 cells with a co-immunoprecipitation assay
similar to that reported by Hayashi and Su [3] showed that the σ1/BiP interaction is observed
concurrently with phosphorylation of σ1 [15]. The authors assert that the σ1/BiP interaction is
modulated by phosphorylation of σ1, as evidenced by their observations that: 1) oxidative stress
increased the level of σ1/BiP complexes and resulted in increased phosphorylation of serine on
σ1 receptors (Ser117 and/or Ser192), and 2) application of (+)-pentazocine prior to oxidative
stress returned the amount of complex to baseline levels and prevented serine phosphorylation
[15]. It is not clear from these studies if formation of the complex requires phosphorylation or if
phosphorylation occurs as a result of complex formation. This is the first report that regulatory
control of σ1 receptors may be influenced by its phosphorylation state. If phosphorylation is
required for a σ1/BiP interaction this has significant implications for development of an in vitro
assay based on either purified recombinant proteins or cell membrane derived preparations.
However, Hayashi and Su’s demonstration that the recombinant GST-Sig-1R116-223 construct
was able to precipitate recombinant BiP or endogenous BiP from crude homogenates of rat
tissues suggests that a σ1/BiP-like complex can form in simple model systems [3].

In the present study Alphascreen was evaluated with a control peptide and with purified tagged
recombinant proteins in buffer solutions and with added detergent and/or lipid. Supporting
studies were performed in an ELISA (enzyme linked immunosorbent assay) format with
solubilized rat liver and CHO cell lysates. The goal of these efforts was to isolate and detect the
σ1/BiP complex reported by Hayashi and Su [3] and determine if an immunologically based
functional assay could be developed that exploited the disruption of this interaction as a read-out
of σ1 receptor activation by agonist ligands. The goals of these studies were: 1) to determine if
Alphascreen provided a viable platform for development of a σ1 activity assay, 2) to determine if
such an assay could be performed with recombinant affinity tagged fusion proteins in buffer or
simple detergent or lipid solutions, and 3) to determine if solubilized rat liver P2 or CHO cell
lysates could serve as suitable sample sources for an Alphascreen based assay.
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5.3 Materials and Methods

5.3.1 Chemicals and reagents and materials
[3H](+)-Pentazocine (specific activity = 29 Ci/mmol) was purchased from Perkin Elmer (Boston,
MA). (+)-Pentazocine, 1,3-di-o-tolylguanidine (DTG), and haloperidol were purchased from
Sigma-Aldrich

(St.

Louis,

MO).

NE100

(4-methoxy-3-(2-phenylethoxy)-N,N-

dipropylbenzeneethanamine hydrochloride) was from Tocris Bioscience (Ellisville, MO). 1 N
Hydrochloric acid, Microscint-20, Costar Untreated polystyrene plates (9017), Costar High Bind
polystyrene plates (9018), Costar Easy Wash High Bind polystyrene plates (3369), Costar
Untreated polyvinylchloride plates (2797), 100X HALT protease inhibitor cocktail and Unifilter96 GF/B filter plates were purchased from Fisher Scientific (Pittsburgh, PA). Dulbecco’s
phosphate buffered saline without Ca2+ or Mg2+ (DPBS without Ca2+/Mg2+) was from Invitrogen
(Carlsbad, CA). Recombinant active human 6X-His BiP (AB78432) was obtained from Abcam
(Cambridge, MA), and the purified human σ1-myc-FLAG protein (TP301206) was from Origene
(Rockville, MD). Alphascreen nickel-chelate donor beads and FLAG-Ab acceptor beads were
from Perkin Elmer (Waltham, MA). Anti-FLAG M2 affinity gel, 3XFLAG peptide, aminoterminal

FLAG-BAP

fusion

protein,

CelLytic

M,

CHAPS,

CaCl2,

tris(hydroxymethyl)aminomethane (Tris), fatty acid free bovine serum albumin (BSA), 2,2’azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) diazonium salt (ABTS), phosphate-citrate
buffer, Tris buffered saline with Tween 20, pH 8 (Tris-Tween, T9039) and the 30% hydrogen
peroxide solution were from Sigma-Aldrich. Mouse anti-human BiP aa525-628 (BD610979)
antibody was from BD Transduction Lab (Franklin Lakes, NJ). Rabbit anti-human BiP aa24-43
(AB32618) and rabbit anti-rat σ1 “c-terminal” (AB53852) were from Abcam. A custom chicken
anti-rat σ1 aa65-78 antibody was purchased from Aves laboratories (Tigard, OR). The mouseanti-FLAG M2 antibody (F1804), horse radish peroxidase (HRP) conjugated goat-anti-mouse
antibody (A9917) and HRP conjugated goat-anti-rabbit antibody (A0545) were from SigmaAldrich. The biotin conjugated rabbit-anti-chicken antibody (G2891) was from Fisher Scientific
and was used in conjunction with streptactin-HRP from Bio-rad (Hercules, CA). Precision Plus
Protein Western C molecular weight markers were also from Bio-rad. SuperSignal West Pico
Chemiluminescent Substrate was from Fisher Scientific.
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5.3.2 Test compound solutions
Stock solutions of (+)-pentazocine, DTG, haloperidol, and NE100 were prepared in DMSO.
Dilutions for use in preparation of samples were made in assay buffers specific to the assay in
which they were used.

5.3.3 CHO cell culture
CHO-K1 cells were obtained from the American Type Culture Collection (Lot number,
58078551, passage number unknown, ATCC; Rockville, MD). Cells were grown in F-12K
medium (ATCC) supplemented with 5% heat inactivated fetal bovine serum (Sigma-Aldrich),
100 units/ml penicillin and 100 µg/ml streptomycin (Sigma-Aldrich). Cells were maintained at
37ºC in 5% CO2. Passage of cells was performed using 0.25% trypsin/0.5 mM EDTA
(Invitrogen; Carlsbad, CA).

5.3.4 CHO cell lysates
CHO cell lysates were prepared in 0.2% CHAPS, 2% CHAPS, or in CelLytic M. For each cell
lysate, cells from two sub-confluent 175 cm2 flasks were harvested in DPBS without Ca2+/Mg2+
and centrifuged at 500 x g for 5 min at 4 ºC. For lysates prepared in CHAPS, solutions
containing 2.5 ml of 0.2% or 2% CHAPS in 50 mM Tris, pH 7.4 with 1X HALT were added to
pelleted cells. For lysates prepared in CelLytic M, a solution of CelLytic M containing 1X
HALT in a total volume of 2.5 ml was added to pelleted cells. The re-suspended cells were
rocked for 1 h at 4 ºC followed by centrifugation at 16,000 x g for 15 min at 4 ºC. Supernatents
were transferred to clean tubes and maintained on ice until use.

5.3.5 Rat liver and Rat brain P2
Rat liver and rat brain P2 homogenates were prepared from frozen tissues obtained from PelFreeze (Rogers, AR). Tissues were homogenized batch-wise with a Potter-Elvehjem
homogenizer (5-10 strokes with motor driven Teflon pestle) in ice-cold 10 mM Tris-sucrose
buffer (0.32 M sucrose in 10 mM Tris, pH 7.4) using 10 ml buffer per g of tissue with ~3 g of
tissue per batch. Homogenates from multiple batches were combined and centrifuged for 10 min
at 1,000 x g, at 4 °C. Supernatants were decanted, combined and centrifuged for 15 min at
31,000 x g, at 4 °C. To reduce levels of bound endogenous ligand(s) the resulting P2 membrane
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was washed as follows: 1) pellets were re-suspended in 10 mM Tris, pH 7.4 using 3 ml buffer
per gram of wet tissue, 2) the resulting suspension was incubated for 30 min at 25 °C, 3)
following incubation, the suspension was centrifuged for 15 min at 31,000 x g, at 4 °C. The
resulting pellets were re-suspended in 10 mM Tris, pH 7.4 buffer at a final concentration of 1 g
starting tissue weight/1.5 ml. Tissue preparations were aliquoted in 1 ml portions and stored at 80 °C. The Bradford assay was used to quantitate protein concentration [37].

5.3.6 CHAPS solubilized rat liver and rat brain P2
Rat liver and rat brain P2 were solubilized in 0.2% CHAPS as follows. A 1 ml aliquot of liver or
brain P2 containing 10 mg/ml total protein was centrifuged at 500 x g for 5 min. Following
aspiration of the supernatant, 1 ml of 0.2% CHAPS in 50 mM Tris, pH 7.4 with 1X HALT was
added to the resulting pellet. The sample was incubated for 60 min with rocking at 4 ºC and
subsequently centrifuged for 15 min at 31,000 x g, at 4 ºC. The supernatant was transferred to a
clean polypropylene tube and maintained on ice until use.

5.3.7 Radioligand binding of rat liver P2 versus solubilized rat liver P2
A standard radioligand binding experiment was performed to compare binding of [3H](+)pentazocine to “native” and solubilized rat liver P2 samples. To determine total binding, 5 nM
[3H](+)-pentazocine was added to 25 µg (total protein) samples of native and CHAPS solubilized
rat liver in a total volume of 0.5 ml of 50 mM Tris, pH 8. Samples for the determination of nonspecific binding were prepared by addition of 10 µM haloperidol. Total and non-specific binding
samples were prepared and processed in parallel. Samples were incubated for 2 h at 25ºC and
filtered through Perkin Elmer Unifilter GF/B filter plates using a Connectorate 96-well harvester
(Dietikon, Switzerland). Samples were washed 5 times with 0.2 ml of 10 mM Tris, pH 8 and air
dried prior to adding scintillation cocktail. Filter plates were soaked in 0.5% polyethyleneimine
(PEI) for 30 min prior to use to reduce non-specific binding. Processed samples were counted on
a Perkin Elmer Microbeta2 2450 microplate counter (Waltham, MA), in the Unifilter plate,
following a 2 h incubation with 40 µl Microscint-20 cocktail per well.
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5.3.8 ELISA assays
A sandwich-type ELISA was utilized to test for capture and detection of the σ1/BiP complex
present in CHAPS solubilized rat liver and rat brain P2. Four different sample plate types were
tested, including plates of different base plastic and treated and untreated plates (Costar product
numbers 2797, 3369, 9017 and 9018). Control samples consisted of adding buffer alone to
antibody coated wells at the appropriate step of the assay. Rat brain P2 served as a second
control as it is known to contain approximately 1/6 the number of σ1 receptors per mg of protein
compared to rat liver P2, so would be expected to generate 1/6 the signal derived from rat liver
P2. The general assay scheme is shown schematically in Figure 1. Sample plates were coated
with σ1 antibody (Aves custom), 100 µl/well, containing 1 or 10 µg/ml antibody in carbonate
buffer, pH 9.6. Plates were incubated overnight at 4 oC. All incubations were accompanied by
gentle agitation on an orbital plate shaker. Following a PBS wash, plates were blocked with 1%
BSA in carbonate buffer, 200 µl/well. Following incubation for 1 h at room temperature (RT),
plates were washed with PBS and samples of 0.2% CHAPS solubilized liver or brain P2
containing 100 µg total protein in 100 µl/well, were added. Control wells were prepared by
addition 0.2% CHAPS, 100 µl/well. To test for ligand and Ca2+ sensitivity, 10 µl of 10X
solutions of CaCl2, (+)-pentazocine, NE100, (+)-pentazocine with CaCl2, or NE100 with CaCl2
were added to samples in wells for final concentrations of 1 mM CaCl2 and/or 1 µM ligand; for
control samples 10 µl buffer was added. Following incubation for 1 h at RT, plates were washed
with PBS containing 1 mM CaCl2 (PBS/Ca2+) followed by addition of 100 µl of a 1/1000
dilution of mouse anti-human BiP aa525-628 antibody (BD610979) or rabbit anti-human BiP
aa24-43 antibody (AB32618). Following incubation for 1 h at RT, plates were washed with
PBS/Ca2+ and 100 µl of a 1/10,000 dilution of HRP conjugated goat-anti-mouse or goat-antirabbit antibody was added. Following incubation for 1 h at RT plates were washed with
PBS/Ca2+ and 100 µl/well ABTS in phosphate-citrate buffer containing hydrogen peroxide was
added. Following 30-60 min of light agitation, plates were read on a Biotek Multi-plate reader
(Winooski, VT) at 405 nM. The ABTS solution was prepared by dissolving 1 tablet (Sigma
P4809) in 100 ml of 0.05 M phosphate-citrate buffer, pH 5.0 and adding 25 μl of fresh 30%
hydrogen peroxide. To confirm that the ABTS/HRP reaction was patent, 10 or 20 µl aliquots of
HRP secondary antibody solutions were added to 100 µl /well of ABTS reagent solution.

110

5.3.9 Capture of σ1/BiP complex on antibody coated polystyrene plates
Antibodies for σ1 and BiP were passively adsorbed to polystyrene plates and tested for capture
of σ1, BiP or the σ1/BiP complex from CHO cell lysates. Treated polystyrene sample plates
(Costar 9018) were coated with both available σ1 antibodies (AB53852, Aves custom) and both
BiP antibodies (BD610979, AB53852) by incubating 100 µl of 2 µg/ml solutions of antibody in
carbonate buffer, pH 9.6, overnight at 4 ºC. Plates were washed with PBS, blocked with 1% BSA
in PBS for 1 h, and washed with PBS prior to application of CHO cell lysates. CHO cell lysates,
100 µl, were incubated in coated wells for 1 h at RT. Following incubation, wells were washed
with 1 mM CaCl2 in PBS. For PAGE/western blot analysis samples were desorbed from plates
by addition of 5 µl of 1X Laemmli buffer (125 mM Tris, pH 6.8, 4% sodium dedecyl sulfate,
20% glycerol and 0.004% bromophenol blue) followed by incubation for 5 min at ambient
temperature with shaking. Four wells for each sample were prepared and combined for loading
on gels. Crude lysates were diluted 1:1 with 2X Laemmli and 10 µl was loaded per lane. Prior to
loading on gels all samples were incubated for 5 min in boiling water.

5.3.10 Alphascreen assays
Preliminary studies focused on demonstrating that the proposed assay scheme could detect the
interaction of purified σ1-FLAG and 6XHis proteins utilizing a nickel chelate donor bead and an
anti-FLAG coated acceptor bead. The general assay scheme shown in Figure 2A is an adaptation
of the scheme proposed for detection of σ1-FLAG and endogenous BiP as shown in Figure 2B.
A control peptide comprised of 6XHis and the FLAG sequence separated by a 12 amino acid
linker (HHHHHH-GASGSAASGSAG-DYKDDDDK) was utilized to determine starting
conditions, define expected signal ranges, and to determine if sigma ligands, buffers or other
additives had an effect on the signal generated by the interaction of the peptide with the
Alphascreen beads. Following determination of appropriate starting conditions, samples
containing purified recombinant σ1-FLAG and 6XHiS BiP were prepared to determine if a
σ1/BiP interaction could be detected, and if the complex was detected, to test its sensitivity to
Ca2+, sigma ligands and EDTA. Samples for all Alphascreen studies were prepared in duplicate
unless otherwise indicated and were read on an Envision Multilabel Microplate Reader (Perkin
Elmer, Waltham, MA). All data reported from Alphascreen studies represent the average of
duplicate determinations for each condition tested.
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5.3.11 Alphascreen with control peptide
To establish starting conditions and test the performance of the proposed Alphascreen scheme
(as illustrated in Figure 2B), preliminary experiments were performed with a control peptide
comprised of an N-terminal 6XHis tag, and a C-terminal FLAG tag, separated by a 12 amino
acid linker (HHHHHH-GASGSAASGSAG-DYKDDDDK). Samples were prepared in 1X
Alphascreen Universal buffer (PBS pH 7.2 with 0.05% BSA, “AU buffer”) and contained 20
µg/ml Alphascreen donor and acceptor beads (nickel-chelate donor and FLAG-Ab acceptor) and
varying concentrations of the 6X-His/FLAG control peptide in a total volume of 50 µl/sample.
To confirm that the signal observed was due to the specific interaction of the control peptide with
the donor and acceptor beads additional samples were prepared containing 200 nM control
peptide with 200 nM FLAG peptide or 200 nM 6XHis-BiP as competitors for binding to the
respective beads. To confirm that the interactions of the tags with their respective beads were
insensitive to sigma test ligands or added Ca2+, additional samples containing 200 nM control
peptide were prepared containing 10 nM DTG, (+)-pentazocine, haloperidol, NE100, or 1 mM
CaCl2.
5.3.12 Alphascreen with purified σ1-FLAG and 6XHis-BiP fusion proteins
Assays with the purified tagged recombinant proteins were performed using conditions
determined with the control peptide. Samples contained 20 µg/ml Alphascreen donor and
acceptor beads, 0.5 mM CaCl2 and 50 nM σ1-FLAG and/or 6XHis-BiP, in AU buffer in a total
volume of 50 µl/well. Sample components were preincubated for one hour at RT in a volume of
30 µl prior to the addition of 20 µl of a solution containing 50 µg/ml of both donor and acceptor
Alphascreen beads in AU buffer. Additional samples were prepared containing EDTA or sigma
ligands to test their effect on signal levels. Peptide control samples were also prepared containing
peptide or peptide with added sigma ligand or EDTA. To test the effect of added CHAPS
detergent or phosphatidylcholine (PC), another set of samples were prepared containing 0.2%
CHAPS, 0.3 mg/ml PC or CHAPS + PC (in AU buffer).
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5.3.13 Capture of σ1-FLAG on FLAG-antibody affinity bead / FLAG pulldown assay
The purpose of this assay was to test if recombinant σ1-FLAG can function in an
immunoprecipitation assay similar to the GST fusion protein (GST-Sig-1R116-223) pulldown
assay described by Hayashi and Su [3]. Samples contained 30 µg anti-FLAG M2 beads, 200 ng
σ1-FLAG, 500 ng 6XHis-BiP, 200 ng σ1-FLAG + 500 ng 6XHis-BiP or 200 ng of the control
BAP-FLAG fusion protein in a total volume of 1 ml of binding buffer (0.5% Nonidet P-40, 50
mM Tris, pH 7.4 and 2 mM Ca2+). Samples were incubated overnight with rocking at 4 ºC.
Beads were washed with three 500 µl aliquots of binding buffer with centrifugation at 8,000 x g
x 30 sec between washes to facilitate complete removal of wash buffer with a crimped pipet tip.
Following the final wash beads were eluted with 20 µl of Laemmli buffer with immersion in
boiling water for 5 min. Non-immunoprecipitated control samples of each protein (and σ1-FLAG
with 6XHis-BiP) were prepared in Laemmli buffer and boiled as for immunoprecipitated
samples.

5.3.14 Western blots
Samples from antibody coated polystyrene plates and the FLAG pulldown assay were separated
by SDS-PAGE and transferred to PVDF membranes for Western blot analysis. To detect σ1, σ1FLAG or BiP, the PVDF membranes were incubated with the respective primary antibodies at
the indicated dilutions: chicken-anti-rat σ1 (Aves custom, 1:8000), mouse-anti-FLAG M2
(F1804, 1:1000), mouse-anti-human BiP (BD610979, 1:10,000) or rabbit-anti-human BiP
(AB32618, 1:10,000). The secondary antibodies, biotin conjugated rabbit-anti-chicken (G2891),
HRP goat-anti-mouse (A9917), or HRP goat-anti-rabbit (A0545), were used at a 1:50,000
dilution. Streptactin-HRP was used at a 1:12,500 dilution. Incubations with antibodies were
typically 1 h at RT with agitation. Washes were performed with Tris-Tween and antibody
solutions contained 1% dried milk. Proteins were visualized by chemiluminescence with
SuperSignal West Pico Chemiluminescent Substrate (Fisher Scientific).
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5.4 Results

5.4.1 Radioligand binding of solubilized rat liver P2
Rat liver P2 homogenate solubilized in 0.2% CHAPS resulted in an extract with similar binding
capacity relative to unsolubilized membrane. Figure 3 shows binding results for non-specific and
total binding for rat liver P2 versus rat liver P2 solubilized in 0.2% CHAPS. This material was
used for the ELISA-format assays outlined below.

5.4.2 ELISA assays
Attempts to run ELISA assays with the Aves σ1 antibody passively absorbed to the plate, using
solubilized rat liver P2 as sample and “end-point” detection, were unsuccessful. Eight trials were
attempted with varying samples and sample plates including: 1) liver P2 and buffer control, 2)
both liver P2 and brain P2 samples in addition to buffer control, 3) with or without addition of
sigma ligands, and 4) with or without CaCl2, in combination with four different sample plates
(Costar 2797, 3369, 9017 or 9018). For all conditions tested either no difference in signal was
observed for the different sample combinations within each trial or if differences were observed
they were not reproducible between trials.
5.4.3 Capture of σ1 or BiP from CHO cell lysates on polystyrene plate coated with σ1 or BiP
antibodies
No capture of σ1 or BiP or evidence of capture of a σ1/BiP complex was observed following
application of CHO cell lysates to polystyrene plates coated with σ1 or BiP antibodies. Figure 4
shows the Western blot of sample wells eluted with gel loading buffer following application of
CHO cell lysates to plates containing σ1 antibodies and probed with the Aves σ1 antibody. No
bands for σ1 were observed for samples eluted from the antibody coated plates. Similarly when
the gel was re-probed with either BiP antibody no bands were observed corresponding to BiP;
however, neither of the BiP antibodies produced signals on any of the blots produced over the
course of these studies. The plates coated with BiP antibodies gave similar results as those coated
with σ1 antibodies, i.e., no bands were observed for σ1. There were notable differences in the
profile observed for the lysates prepared with the different solubilization agents, where the 0.2%
CHAPS sample contained one band corresponding to σ1, and 2% CHAPS and CelLytic M
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samples contained an additional unidentified band at ~75 kDa. The band for σ1 was most intense
for samples prepared with CelLytic M; the unidentified 75 kDa band was also most prominent in
the CelLytic M lysate sample.

5.4.4 Alphascreen with 6XHis/FLAG control peptide
The addition of the 6XHis/FLAG control peptide to Alphascreen beads generated signal in a
concentration-dependant manner as shown in Figure 5. The concentration-response function
shows a wide dynamic range spanning ~3 nM to ~3 µM added peptide. As shown in Figure 6,
the signal generated in the presence of 200 nM control peptide was unaffected by the addition of
any of the sigma ligands tested at a 10 µM concentration, suggesting that sigma ligands have no
effect on the association of the fusion tags with their respective capture bead or any detrimental
effect on the signal. Similarly the addition of CaCl2 had no effect on the signal. Because added
Ca2+ is required to facilitate the σ1/BiP interaction it was important that it had little or no effect
on the signal. Addition of 6XHis-BiP or 3X-FLAG peptide at a concentration equal to the
concentration of added control peptide (200 nM) reduced the signal substantially as would be
predicted if signal was produced by the specific interaction of the control peptide tags with their
respective Alphascreen beads.
5.4.5 Alphascreen with σ1-FLAG and 6XHis-BiP fusion proteins in Alphascreen Universal buffer
As shown in Table 1, incubation of Alphascreen beads with σ1-FLAG in AU buffer in the
absence of 6xHis-BiP generated a substantial fluorescent signal. The same level of signal was
observed in the sample prepared with σ1-FLAG + 6xHis-BiP; this signal was reduced to
background levels by the addition of EDTA. These results suggest that σ1 interacts with the
nickel-chelate donor bead directly and that this interaction can be mitigated upon chelation of the
bead bound nickel by EDTA. Divalent cations are known to allosterically inhibit binding of
[3H](+)-pentazocine to σ1 [38]. However, it is not certain that the current situation is the result of
σ1 binding to Ni2+ chelated to the bead, or is the result of another non-specific interaction, or
aggregation. The addition of sigma agonist ((+)-pentazocine) or antagonist (NE-100) did not
appear to have an effect on the Alphascreen signal for samples containing σ1-FLAG + 6xHisBiP. No difference was observed in samples containing σ1-FLAG + 6xHis-BiP in the presence
or absence of CaCl2. The addition of sigma ligands also had no effect on the fluorescent signal
115

generated in the peptide control samples. The exclusion of CaCl2 from the control peptide sample
had no effect on the signal relative to samples prepared with 0.5 mM CaCl2. The addition of
EDTA to the peptide control sample reduced the fluorescent signal substantially suggesting the
signal observed in the absence of EDTA is due to the interaction of the control peptide with the
chelated Ni2+ of the donor beads and with the acceptor beads.
5.4.6 Alphascreen with σ1-FLAG and 6XHis-BiP fusion proteins in CHAPS and/or added
phosphatidylcholine
Samples run in the previous experiment were prepared in PBS/CaCl2 buffer. To test if CHAPS or
added lipid could mitigate the interaction of σ1-FLAG with the donor bead and/or promote the
specific interaction of σ1-FLAG and 6XHis-BiP fusion proteins, a similar Alphascreen
experiment was performed as previously described. The overall signal for all samples prepared
with CHAPS or PC was lower relative to samples prepared in the PBS buffer (Alphascreen
Universal buffer), but signal due to σ1-FLAG alone relative to σ1-FLAG + 6XHis-BiP was
similar with all buffer solutions. Interestingly, for samples prepared with 0.2% CHAPS, PC or
CHAPS/PC, the addition of sigma ligands increased the signal relative to samples containing σ1FLAG or σ1-FLAG + 6XHis-BiP alone. Samples prepared in CHAPS/PC gave a similar signal
for all samples containing either or both of the recombinant proteins in the absence of sigma
ligands. The signal due to 6XHis-BiP alone in this buffer suggests additional non-specific
interactions occur in this assay matrix relative to the other matrices tested.
5.4.7 FLAG Pulldown with σ1-FLAG and FLAG affinity matrix
Pulldown of recombinant σ1-FLAG from a solution of 0.5% Nonidet P-40, 50 mM Tris, pH 7.4
and 2 mM Ca2+ was unsuccessful, but the bacterial alkaline phosphatase-FLAG (BAP-FLAG)
fusion protein used as a control sample was successfully precipitated in this system. Figure 7
shows that samples containing σ1-FLAG or σ1-FLAG + His-BiP loaded directly on the gel gave
a strong signal for σ1-FLAG at ~25 kDa following blotting of the PVDF membrane with the
anti-FLAG antibody. Similar samples subjected to immunoprecipitation using the same buffer
used by Hayashi et al. [3] for successful pulldowns of BiP with the GST-fusion system do not
show bands corresponding to σ1-FLAG. The BAP-FLAG control sample was successfully
immunoprecipitated in this buffer as evidenced by a strong band at 50 KDa for both the sample
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loaded directly on the gel and for the immunoprecipitated sample.

5.5 Discussion

The results from these preliminary experiments did not establish that an Alphascreen assay based
on the interaction of σ1 and BiP would result in a viable system for quantitation of the functional
activity of σ1 ligands. However, the experiments performed to test this system did provide
valuable data for future studies. The model Alphascreen scheme originally intended for use with
CHO cells expressing σ1-FLAG yielded equivocal results with recombinant proteins due to an
apparent interaction of the σ1-FLAG protein with the Alphascreen nickel-chelate donor bead.
This interaction may be the result of association of the σ1 receptor with the chelated Ni2+.
Conditions which might be expected to disrupt this interaction, e.g. high Ca2+ concentrations, are
also likely to affect the interaction of the σ1-FLAG protein with BiP to such an extent that the
agonist sensitive behavior of the σ1/BiP complex would be masked. Tests of the proposed
Alphascreen scheme with the control peptide produced a dose-dependant signal that was
unaffected by high concentrations of sigma ligands or added CaCl2, suggesting that under
appropriate conditions Alphascreen may still be a viable format for a functional assay based on
the σ1/BiP interaction. Despite the problems encountered, the theoretical basis for the assay
remains compelling. Recent studies showing successful immunoprecipitation of the σ1/BiP
complex from crude cell lysates of wild-type RGC-5 cells [15] suggest that the endogenously
expressed σ1/BiP complex can be isolated with relative ease with the proper combination of
cells, detergent, and σ1 antibody. This is in contrast to the necessity of isolating MAM to
observe the complex present in wild-type CHO cells solubilized in CHAPS [3]. Because we were
unsuccessful in our attempts to isolate MAM, this simplified method for isolating a patent
σ1/BiP complex from crude cell lysates may hasten future efforts to develop a functional assay
based on the σ1/BiP interaction.
Our initial intention was to utilize cell lysates from CHO cells expressing σ1-FLAG as input for
the Alphascreen assay, similar to Hayashi and Su’s original work with CHO cells expressing σ1EYFP [3], but attempts to clone the vector were unsuccessful. MAM was also an intended input
for Alphascreen, and efforts to isolate MAM from rat liver P2 and CHO cells were made, but no
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bands were observed on Western blots, corresponding to the σ1 receptor, in the isolated
fractions. Additionally, radioligand binding suggested that the isolates were not materially
different from the P2 fraction that served as the starting material for MAM isolation; no
enrichment of binding was observed on a per mass basis compared to the P2 starting material.
Because efforts to isolate a fraction that could unequivocally be identified as MAM were
unsuccessful, the experiments with rat liver P2 and CHO cell lysates were performed as
described below. Recombinant σ1-FLAG became commercially available soon after these
problems were encountered, enabling studies to assess the basic functionality of Alphascreen
with purified σ1 and BiP proteins.
ELISA methods were utilized to make a preliminary assessment of the feasibility of capturing σ1
or the σ1/BiP complex from rat liver P2 with our custom σ1 antibody passively adsorbed to
ELISA plates. This would support use of endogenously expressed sigma receptors in conjunction
with our custom σ1 antibody in an Alphascreen assay. Rat liver P2 contains a relatively high
level of σ1 (~3 pmol/mg); therefore, we believed CHAPS lysates of this material may contain
sufficient concentrations of σ1 for detection. However, because numerous experiments with the
CHAPS solubilized rat liver P2 tested in the proposed sandwich ELISA format resulted in
irreproducible data, a more systematic approach was undertaken where multiple σ1 and BiP
antibodies were tested for capture of their cognate binding partners from CHO lysates
irrespective of the σ1/BiP interaction.
Experiments with two different σ1 antibodies, and two different BiP antibodies, passively
adsorbed to the ELISA plates, failed to effect capture of the σ1 receptor from CHO lysates.
Failure to capture σ1 with the two σ1 antibodies tested may have been the result of the antibodies
binding on the plastic surface in an orientation that did not support an interaction with σ1. Use of
passively adsorbed antibodies is an accepted practice and often yields usable results; however, it
is highly dependant on the specific antibody and can result in as little as 3-10% of bound
antibody capable of capturing antigen [39]. Because the total amount of σ1 receptor applied to
the ELISA plates was ~80 times greater than the amount that was directly loaded and
successfully visualized on the Western blot, this suggests that if even a small fraction of the σ1
applied to the plate was captured it should have been detected on the Western blots. It should be
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noted that our custom polyclonal σ1 antibody targets a different region (residues 65-78) of the rat
σ1 receptor than the antibodies successfully employed by Hayashi and Su (residues 52-69) [3]
and Ha et al. (residues 143–165) [15] in their immunoprecipitation experiments. The Abcam σ1
antibody (ab53852) target sequence is proprietary, but is described as targeting the “C-terminal
region”; this antibody has been demonstrated to work with Western blotting but has not been
validated for use with immunoprecipitation. While our custom σ1 antibody has been successfully
utilized for Western blots, and for flow cytometry with fixed and permeabilized NG-108 cells
(unpublished data produced in our laboratory), it is not known if it is σ1 binding competent
under other conditions. The Western blots for BiP have been inconclusive over the course of this
project; therefore, no conclusion can be made regarding the success or failure to capture BiP.

The Western blots from the above experiments showed that the crude CHO cell lysates prepared
in CelLytic M or 2% CHAPS yielded a different population of sigma receptors than are produced
using 0.2% CHAPS. In the CelLytic and 2% CHAPS lysates an additional strong band was
observed at molecular weight ~75 kDa that may represent a complex of σ1 with lipid or protein.
This is consistent with reports that different detergents and solubilization conditions result in
isolation of different molecular complexes of σ1, as determined by gel exclusion
chromatography [29-32]. This is relevant because it is not known if a functional σ1/BiP complex
can be isolated using a wide range of solubilization conditions or if one can be isolated at all. In
light of the report by Ha et al. [15] of immunoprecipitation of a σ1/BiP complex from crude
lysates of RGC-5 cells, solubilized with a detergent mixture that was substantially different than
that utilized by Hayashi and Su [3], it appears that successful co-precipitation of a σ1/BiP
complex can be effected from multiple sources with varied detergents. However, because neither
group demonstrated the functional activity of the isolated complex with exogenous addition of
sigma ligands it is not known if either or both isolates contain the necessary components required
of a functional complex.

Assays with Alphascreen were performed with a control peptide and purified recombinant tagged
σ1 and BiP (σ1-FLAG and 6XHis-BiP). The results with the model peptide suggested the assay
worked as designed with the Alphascreen donor and acceptor beads being pulled together via
their interactions with 6XHis and FLAG sequences flanking a neutral 12 amino acid linker
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sequence. Studies with the recombinant proteins showed that σ1-FLAG in the absence of 6XHisBiP generated a signal of equal intensity compared to when both tagged proteins were added.
This suggested that σ1-FLAG was interacting with both the FLAG-Ab acceptor bead, and the
nickel-chelate donor bead. Added detergent or lipid (PC) did not appear to discourage the
interaction of σ1-FLAG with the nickel chelate bead. It is interesting that the very high
concentrations of sigma ligands tested in the experiments with neat buffer (without detergent or
lipid) did not appear to affect this interaction, although this is not certain as ligand was not added
to a sample containing σ1-FLAG alone; it was only tested in the presence of σ1-FLAG + 6XHisBiP. For samples prepared with 0.2% CHAPS, PC or CHAPS/PC, the addition of sigma ligands
increased the signal relative to samples containing σ1-FLAG or σ1-FLAG + 6XHis-BiP alone.
This suggests that binding of sigma ligand to σ1-FLAG may have occurred in these samples and
that this interaction increases the association of σ1-FLAG with the donor bead, increases the
interaction of σ1-FLAG with 6XHis-BiP, promotes both interactions, or promotes additional
non-specific interactions of either or both proteins with the beads. Because no samples were
prepared containing only σ1-FLAG or 6XHis-BiP this cannot be reconciled with the current data.
It was known that divalent cations can non-competitively inhibit the binding of [3H](+)pentazocine to guinea-pig cerebellum membranes [38] but it was not anticipated that this would
result in σ1-FLAG associating with the nickel-chelate donor bead. However, the association may
be the result of other non-specific interactions unassociated with the bead bound Ni+2, but
because CHAPS or added lipid did not disrupt this interaction, it does not appear to be a result of
non-specific hydrophobic interactions.
Because of the unanticipated interaction of σ1-FLAG with the nickel chelate bead, a simplified
system was adopted in an effort to capture σ1-FLAG and/or a σ1-FLAG/6XHis-BiP complex
with subsequent detection by Western blot. This system mimicked Hayashi and Su’s [3]
pulldown of recombinant BiP using the GST-Sig-1R116-223 construct. An NP-40 based buffer
was used as assay buffer in their experiments, suggesting that the σ1/BiP interaction can occur in
the absence of lipids, similar to the interaction of purified σ1 with ligands [40]. Therefore, to test
if this buffer would support capture of the σ1-FLAG fusion protein used in our Alphascreen
assay, and to test if this system could support a detectable σ1/BiP interaction, a conventional
immunoprecipitation procedure was performed with a FLAG affinity matrix. In this experiment
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the bacterial alkaline phosphatase-FLAG control was immunoprecipitated but the σ1-FLAG was
not. Because this material appeared to interact readily with the Alphascreen beads in the PBS,
CHAPS and phosphatidylcholine buffers, this result suggests that σ1-FLAG may aggregate in
the NP-40 buffer preventing interaction with the FLAG affinity matrix. Successful Western blot
detection of the σ1-FLAG control samples loaded directly on the gel, blotted with the FLAG
antibody, supports this assumption.

Based on the results observed in our studies and more recent work of Hayashi and Fujimoto [34]
and Ha et al. [15], a number of alternative experiments are proposed. Briefly, the easiest
experiment to perform would be to acquire a rabbit derived σ1 antibody similar to the one
prepared by Ha et al. [15], and duplicate their sample preparation and immunoprecipitation
procedure [15]. Samples would consist of RGC-5 cells exposed in situ to sigma ligands and
samples prepared by exposing lysates from naïve RGC-5 cells exposed exogenously to sigma
ligands. This system may very quickly verify or negate the validity of the overall approach and
provide most of the information necessary to design the appropriate Alphascreen scheme. In the
absence of an available rabbit derived σ1 antibody our chicken antibody should be biotinylated,
captured on streptavidin coated magnetic beads, and used in immunoprecipitation with RGC-5
lysates as described above. A second potential input for the assay which precludes the isolation
of MAM by Percoll gradient centrifugation involves preparing Tx-114 detergent resistant
membranes (DRM) from CHO cells using an adaptation of the method described by Hayashi and
Fujimoto as outlined in Figure 8 [34]. Hayashi and Fujimoto demonstrated that the DRM
obtained by Tx-114 solubilization of CHO cells is essentially the same material that is isolated
from P2 using Percoll gradient centrifugation [34] and thus may provide a more reliable method
for obtaining MAM from CHO cells.

The efforts presented in this study would have benefited from better Western blot
characterization of the solubilized rat P2 membranes and CHO lysates isolates prior to their use
in experiments. The inability to produce a usable blot with our BiP antibodies was also a major
hindrance. The experiment testing the ability to capture σ1 or BiP by passive adsorbtion of
antibodies on an ELISA sample plate did not inform us if this was the result of a poor antibody
antigen interaction or if the antibodies were poorly oriented on the plastic surface. As stated
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previously it would have been preferable to biotinylate our custom σ1 antibody and present it via
a streptavidin coated plate or bead. Lastly, while some useful information was learned about the
basic operation of Alphascreen, the experiments were inconclusive with regard to its future use
in an assay based on the interaction of σ1 and BiP.

Future efforts should emphasize the use of tissue or cultured cell derived, constitutively
generated, σ1/BiP complex as this alleviates the necessity of extensive molecular biology efforts
and the possibility that overexpression systems may not faithfully reproduce the functional
interaction that occurs in vivo or that affinity tags interfere with the σ1/BiP interaction. Similarly,
a cell free system utilizing purified recombinant affinity tagged proteins would likely require
significant effort to reconstitute in an artificial lipid environment, which we now know should be
highly enriched in cholesterol and ceramide. Additionally if phosphorylation of σ1 does indeed
regulate its interaction with BiP, biological sources of σ1 and BiP may be the only way to
faithfully recapitulate the endogenous situation in a model system. Because the Alphascreen
platform can accommodate the use of almost any antibody, the primary limitation that would
preclude its use would be incompatibility with the detergent solutions utilized to isolate
functional σ1/BiP complexes identified using immunoprecipitation.

In conclusion, we did not determine if Alphascreen will provide a suitable platform for the
analysis of σ1 functional activities based on the interaction of σ1 and BiP. The current studies
also failed to determine if the σ1/BiP interaction can be observed with recombinant affinity
tagged fusion proteins in buffer or simple detergent or lipid solutions. While the choice of the
nickel chelate donor bead was unfortunate it is not clear why σ1 interacts with this material with
such high avidity. The σ1-FLAG protein appears to interact with the FLAG acceptor bead in
PBS buffer and 0.2% CHAPS (presumably via antigen:antibody interaction) but the FLAG tag
appears to be unavailable for binding with the anti-FLAG affinity matrix in a simple NP-40
buffer. Our experiments also did not determine if solubilized rat liver P2 or CHO cells would
serve as a suitable input for Alphascreen; however, the use of biotinylated or IgG antibodies with
conventional immunoprecipitation on streptavidin or protein A/G matrices would likely provide
more definitive answers than the passive adsorbtion of antibodies used in our studies. Use of
wild-type CHO or rat liver isolates may require extensive experimentation with detergents, or
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additional purification to yield σ1 enriched material, but may be as simple as isolating Tx-114
DRM from either receptor source. However, prior to embarking on any additional new
approaches it is reasonable to propose that the RGC-5 cell/detergent cocktail utilized by Ha et al.
[15] may provide the simplest means for determining if the σ1/BiP complex in lysates exposed
exogenously to sigma ligands behaves as it does in intact cells.
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Figure 1. General scheme for detection of tissue or cultured cell derived σ1/BiP complex using
ELISA platform.

A

B

Figure 2. General scheme for detection of interaction of σ1-FLAG with (A) 6XHis-BiP or (B)
endogenous BiP.
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Figure 3. Binding of [3H](+)-pentazocine to rat liver P2 and P2 solubilized in 0.2% CHAPS.
Approximately 25 µg total protein was incubated with 5 nM [3H](+)-pentazocine in the presence
(blank) or absence (total) of 10 µM haloperidol. Data are averages of triplicate determinations;
error bars indicate the standard error of the mean.
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Figure 4. Western blot following attempt to capture σ1 from CHO cell lysates on antibody
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Figure 5. Titration of Alphascreen beads with control peptide shows a wide dynamic range, low
signal to background ratio, and the expected “hooking” effect at high peptide concentrations.
Samples contained 20 µg/ml donor and acceptor Alphascreen beads and varying concentrations
of the 6X-His/FLAG control peptide in 1X Alphascreen universal buffer (PBS) in a total volume
of 50 µl/sample. The EC50 for this interaction was ~125 nM.
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Figure 6. Effect of added CaCl2, sigma ligand, or competitor for donor or acceptor beads.
Purified 3XFLAG peptide and recombinant 6XHis-BiP were capable of reducing signal derived
from the control peptide, presumably via competitive interaction with the acceptor and donor
beads respectively. Samples contained 20 µg/ml donor and acceptor Alphascreen beads, 200 nM
6X-His-FLAG control peptide and the indicated test ligands in 1X Alphascreen universal buffer
in a total volume of 50 µl/sample. CaCl2 and sigma ligands were at 1 mM and 10 µM final
concentration respectively. Data are averages of duplicate samples prepared for each condition
tested.
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Table 1. Alphascreen signal produced by recombinant σ1-FLAG and 6XHis-BiP versus control
peptide. Samples contained 50 nM σ1-FLAG and/or 50 nM 6XHis-BiP, 0.5 mM CaCl2, and 20
µg/ml donor and acceptor bead in PBS pH 7.2 with 0.05% BSA. Proteins, CaCl2, EDTA and
ligands were pre-incubated 1 hour prior to bead addition. Samples with added sigma ligand
contained 100 nM or 10 µM ligand as indicated. Tabulated data are averages of duplicate
samples prepared for each condition tested.

Fluorescence Units

Sample
PBS

1

0.2% CHAPS

2

PC

2

0.2% CHAPS/PC

Blank

9096

3714

7932

σ1-FLAG + 6XHis-BiP

63761

8086

23439

20060

σ1-FLAG

56020

7849

24433

22768

6XHis-BiP

12079

4175

13184

18980

σ1 + BiP + (+)-pentazocine

65710

11950

53432

26247

σ1 + BiP + NE100

70443

11813

58370

29503

σ1 + BiP No CaCl2

62477

-

-

-

σ1 + BiP + EDTA

25944

-

-

-

Peptide

137698

47358

90100

60506

Peptide + (+)-pentazocine

122370

37220

87748

50884

Peptide + NE100

115377

43999

99429

48921

Peptide No CaCl2

121883

-

-

-

Peptide + EDTA

31941

-

-

-

1

[Sigma ligand] = 10 µM

2

[Sigma ligands] = 100 nM
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Figure 7. FLAG pulldown of σ1-FLAG and BAP-FLAG. Contiguous lanes contain nonimmunoprecipitated controls alongside the indicated immunoprecipitated protein(s). The PVDF
membrane was blotted with FLAG-Ab. Lane 1 is a blank immunoprecipitate control. Lanes 4
and 6 show a strong band for σ1-FLAG (~25 kDa) that is absent in immunoprecipitated matching
samples in lane 5 and 7. The bacterial alkaline phosphatase-FLAG sample in lane 9 shows that
BAP-FLAG is successfully immunoprecipiated under these conditions.
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Preparation of Tx-114 DRM from tissue or cells
0.5% Tx-114, 10 mM Tris 7.4,
150 mM NaCl, 5 mM EDTA,
PMSF and aprotinin
30 m @ 4ºC

DRM from 2) into 0.2% CHAPS, 10
mM Tris 7.4, 2 h @ 4ºC
Centrifuge supernatent from
step 1, containing DRM, for 60
m at 100,000xg

Sonicate 10 s x 3

Centrifuge 60 m at 100,000xg

Centrifuge 20 m at 12,000xg

1

2

insoluble debris

3

DRM containing sigma1R

solubilized
sigma1R

CHAPS insoluble
DRM
components

Figure 8. Procedure for preparation of σ1/MAM enriched fractions with Tx-114. Samples are
lysed in 0.5% Tx-114 buffer followed by centrifugation at 12,000 x g. The resulting supernatant
is centrifuged at 100,000 x g to pellet σ1/DRM. The resulting pellet is solubilized in 0.2%
CHAPS buffer. Samples should be analyzed for the presence of σ1 and BiP prior to use in
immunoprecipitations for the σ1/BiP complex and subsequent testing of the isolated complex for
sensitivity to exogenously added sigma ligands.
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SUMMARY
In conclusion, our studies have resulted in: 1) the characterization of a new σ1 receptor selective
radioligand, and demonstration of its utility in competition binding studies, 2) the development,
validation and application of a new 96-well filtration based radioligand binding method for the
analysis of sigma receptor ligands, and 3) demonstration that scintillation proximity assay (SPA)
technology is a suitable platform for radioligand binding studies of sigma receptor ligands.
Efforts to demonstrate that the ligand sensitive interaction of the σ1 receptor with binding
immunoglobulin protein (BIP) can form the basis of an in vitro functional assay for σ1 receptor
activity were unsuccessful; however, the studies performed and the presentation of the concept
may provide useful information for future efforts by other researchers.
Our studies show that [3H]SN56 can serve as an alternative to [3H](+)-pentazocine in radioligand
binding assays. [3H]SN56 exhibits saturable and reversible binding to a single high affinity site
in rat brain membranes that corresponds to the site labeled by the selective σ1 receptor
radioligand [3H](+)-pentazocine. Further, because SN56 is a σ1 receptor antagonist, while (+)pentazocine is an agonist, future studies with the radiolabeled forms of these ligands may reveal
information that distinguishes functionally active versus inactive ligands. Therefore, our
characterization of [3H]SN56 demonstrates that this radioligand represents an important new tool
for sigma receptor research.

The 96-well filtration based competition binding assay presented in this dissertation is a
significant improvement over the conventional Brandel filtration based method. The 96-well
method reduces waste and increases throughput dramatically while generating comparable data
relative to the conventional method. Excellent correlations were observed between the two
methods for the determination of binding to both σ1 and σ2 subtypes despite the use of different
assay formats and tissue source for sigma receptors. The validity of the method was further
demonstrated by a successful structure-binding affinity analysis of a novel series of 2(3H)benzothiazolone sigma receptor ligands. The study of this compound series identified several
new high affinity σ1 selective ligands and generated data which will be useful for the
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development of pharmacophore models for both sigma receptor subtypes, and consequently
provides for the rational design of future novel sigma ligands.

Our preliminary assessment of SPA for use in competition binding assays of sigma receptor
ligands suggests this technology has promise for future use in high throughput screening (HTS).
Currently there are some issues that need to be resolved before the method is generally
applicable, which include: a high background signal, very long incubation times, and a relatively
high per sample cost for SPA beads. These problems may be resolved through the use of more
highly purified tissue membrane preparations, cells lines overexpressing sigma receptors and/or
the use of radioligands with higher specific activities. Because this method is amenable to HTS it
may be desirable to continue further development; this depends largely on the interest of the
science community in sigma receptor based therapeutics.
Our studies supporting the development of a high throughput in vitro functional assay for σ1
ligands based on the agonist sensitive interaction between σ1 and BiP were largely unsuccessful.
However, the need for an in vitro functional assay remains and the rational for targeting this
interaction is sound. Future efforts should focus on demonstrating that a patent σ1/BiP complex
can be isolated using conventional immunoprecipitation methods and cell lines where the
interaction has already been established. This includes wild-type Chinese hamster ovary and
RGC-5 cells. The isolation of a solubilized functional complex from these cells will likely be
largely dependant on finding appropriate detergent conditions. Additional efforts to adapt the
method to higher throughput methods should only be attempted following demonstration that a
solubilized functional complex can be isolated.
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